NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE

Abstract
[Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided.
Description
TECHNICAL FIELD

The present invention relates to pharmaceuticals, particularly to nitrogenous-ring acylguanidine derivatives with 5-HT5A receptor modulating action, useful as an agent for treating or preventing dementia, schizophrenia, and the like.


BACKGROUND ART

In recent years, it has been suggested that the 5-HT5A receptor which is one of the subtypes of serotonin receptors plays an important role in dementia and schizophrenia. For example, it has been reported that new exploratory behaviors are increased in the 5-HT5A receptor knock-out mice, and hyperactivity by LSD is inhibited in the 5-HT5A receptor knock-out mice (Neuron 22, 581-591, 1999). From the results of gene expression analysis, it has been reported that the 5-HT5A receptor is highly expressed in human and rodent brain, and in brain, it is highly expressed in hippocampal CA1 and CA3 pyramidal cells which are related to memory, and frontal lobe (cerebral cortex) which is deeply related to schizophrenia (Molecular Brain Research 56, 1-8, 1998). Furthermore, it has been reported that gene polymorphism of the 5-HT5A receptor relates to schizophrenia (Neuroreport 11, 2017-2020, 2000; Mol. Psychiatr. 6, 217-219, 2001; and J. Psychiatr. Res. 38, 371-376, 2004). Accordingly, it is suggested that regulation of 5-HT5A receptor action leads to the improvement of dementia and schizophrenia and compounds with such function are needed.


Hitherto, several kinds of compounds having affinity for a 5-HT5A receptor have been reported.


For example, it is described that bicyclic acylguanidine derivatives represented by the following general formula bind to the 5-HT5A receptor, and are thus used for treating dementia, schizophrenia, and the like (Patent Document 1).




embedded image


(A represents phenyl or the like, R1, R2, and R3 each represent H, lower alkyl, halogen, or the like, R7 and R8 each represent H, lower alkyl, or the like, X represents O, S, or CR9aR9b, R9a and R9b each represent H or the like, the dotted line represents a bond or absence, m represents 0, 1, or 2, L1 and L2 each represent a bond or the like, and R4, R5, and R6 each represent H or the like. For details, refer to the publication.)


In the publication, there is no disclosure on those in which the bicyclic ring group has a N atom containing ring.


In addition, it is reported that compounds having a tricyclic acylguanidine structure (Patent Document 2) and compounds having a structure in which the ring is directly bonded to the guanidine (Patent Document 3) each bind to the 5-HT5A receptor, and are used for treating dementia, schizophrenia, and the like.


Furthermore, it is described that quinoline derivatives represented by the following general formula bind to a 5-HT5A receptor, and are used for treating dementia, schizophrenia, and the like (Patent Document 4).




embedded image


(R1 represents —C(O)NRcCH2—Ar1 or the like, R2 represents —Ar2, —CHRd—Ar2, —CH2CH2O—Ar2, or the like, R3 represents phenyl or pyridinyl, which may be substituted, Ar1 and Ar2 each represent aryl or heteroaryl, which may be substituted, and Rc and Rd each represent a hydrogen atom or C1-7-alkyl. For details on these, refer to the publication.)


In the publication, there is no disclosure on those having acylguanidine as R1.


Hitherto, there is no report for a 5-HT5A receptor modulator which has a structure in which the guanidine is bonded to a bicyclic nitrogen-containing ring via a carbonyl group.


In addition, naphthalene ring derivatives substituted with an acylguanidino group have been reported in Patent Document 5. This document relates to a naphthylacylguanidine derivative, but does not disclose the quinoline derivative of the present invention. Further, the application of the compound of this document is an antiviral agent.


LIST OF THE DOCUMENTS
Patent Documents



  • Patent Document 1: WO 2009/022633 pamphlet

  • Patent Document 2: WO 2008/096791 pamphlet

  • Patent Document 3: WO 2005/082871 pamphlet

  • Patent Document 4: WO 2009/040290 pamphlet

  • Patent Document 5: WO 2006/135978 pamphlet



SUMMARY OF THE INVENTION
Problem that the Invention is to Solve

The object of the present invention is to provide excellent agents for treating or preventing dementia, schizophrenia, and the like, based on 5-HT5A receptor modulating action.


Means for Solving the Problem

The present inventors have extensively studied compounds having 5-HT5A receptor modulating action, and as a result, it has been found that acylguanidine derivatives which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on said 5-HT5A receptor modulating action, and thus can be excellent agents for treating or preventing dementia, schizophrenia, and the like, thereby completing the present invention.


Compound of formula (I) is characterized by the quinoline or isoquinoline structure, good metabolism profile and safety.


That is, the present invention relates to compound of formula (I) or pharmaceutically acceptable salts thereof.




embedded image


(wherein the symbols have the following meanings:




embedded image


aryl, cycloalkyl, cycloalkenyl or monocyclic nitrogen-containing heterocyclic group,


Z1, Z2, Z3, Z4 and Z5: one of any of them is a nitrogen atom, and the others are carbon atoms, in which the nitrogen atom is optionally oxidized to form an N-oxide,


R1, R2 and R3: each independently represents H, lower alkyl, halogen, halogeno-lower alkyl, —CN, —NO2, —ORa, —S-lower alkyl, —O-halogeno-lower alkyl, —CO2Ra, —C(O)NRbRc, —SO2-lower alkyl, or -lower alkylene-ORa,


R4, R5 and R6: each independently represents H, lower alkyl, cycloalkyl, halogen, halogeno-lower alkyl, —CN, —NO2, —ORa, —S-lower alkyl, —O-halogeno-lower alkyl, —CO2Ra, —C(O)NRbRc, —SO2-lower alkyl, or lower alkylene-ORa,


Ra, Rb and Rc: each independently represents H or lower alkyl, and


R7 and R8: each independently represents H or lower alkyl.)


Unless otherwise specifically noted, in the present specification, when a symbol in a chemical formula is used in another chemical formula same symbols have the same meanings.


Furthermore, atoms from Z1 to Z5 in formula (I), that are carbon atoms and do not bond to any of R4, R5, and R6 are substituted with H.


Furthermore, the present invention relates to pharmaceutical compositions containing a compound of the above formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and, for example, the above pharmaceutical composition which is a 5-HT5A receptor modulator. In another example, the present invention relates to the above pharmaceutical composition, which is an agent for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder; and further as another example, it relates to the above pharmaceutical composition which is an agent for preventing or treating dementia or schizophrenia.


In another embodiment, the present invention relates to 5-HT5A receptor modulators, for example, agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder; further as another example, it relates to use of compound of the above formula (I) or a pharmaceutically acceptable salt thereof for prevention or treatment of dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder; further as another example, it relates to use of compound of the above formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of an agent for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder or a method for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, or a method for preventing or treating dementia or schizophrenia in which the method includes administering a therapeutically effective amount of compound of the above formula (I) or a pharmaceutically acceptable salt thereof to a mammal. The above said schizophrenia includes positive symptoms, negative symptoms, cognitive impairment, and mood disorders.


Effects of the Invention

Compounds of formula (I) have the advantage of potent 5-HT5A receptor modulating action and excellent pharmacological action based thereon. The pharmaceutical compositions of the present invention are useful for treatment or prevention of 5-HT5A receptor-related diseases, particularly for treatment or prevention of dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.







MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention is described in detail.


In the present specification, the “5-HT5A receptor modulator” is a generic term referring to a compound that inhibits activation of the 5-HT5A receptor by antagonizing with an endogenous ligand (5-HT5A antagonist), and a compound that shows function by activation of the 5-HT5A receptor (5-HT5A agonist). Examples of the “5-HT5A receptor modulating action” include a 5-HT5A antagonist.


The “lower alkyl” means a linear or branched alkyl group having 1 to 6 carbon atoms (hereinafter abbreviated as C1-6), specifically, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl group, or the like. In another embodiment, it is C1-4 alkyl, and in a still another embodiment, methyl, ethyl, n-propyl, or isopropyl.


The “lower alkylene” is a linear or branched C1-6 alkylene, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, propylene, methylmethylene, ethylethylene, 1,2-dimethylethylene, 1,1,2,2-tetramethylethylene, and the like. In another embodiment, it is C1-4 alkylene, in a still another embodiment, methylene or ethylene, and in a further still another embodiment, methylene.


The “cycloalkyl” is a C3-10 saturated hydrocarbon ring group, which may have a bridge. Specifically, it is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl group, or the like, in another embodiment, C3-6 cycloalkyl group, and in a still another embodiment, cyclopropyl group.


The “cycloalkenyl” is a C5-10 cycloalkenyl, in another embodiment, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl group, or the like, and in a still another embodiment, cyclopentenyl or cyclohexenyl group.


The “halogen” means F, Cl, Br, or I. In a certain embodiment, it is F or Cl.


The “halogeno-lower alkyl” is a C1-6 alkyl group substituted with one or more halogen atoms. In a certain embodiment, it is a C1-6 alkyl group substituted with 1 to 5 halogen atoms, and in another embodiment, difluoromethyl or trifluoromethyl group.


The “aryl” is a C6-14 monocyclic to tricyclic aromatic hydrocarbon ring group, and in a certain embodiment, it is phenyl or naphthyl group, and in another embodiment, a phenyl group.


The “monocyclic nitrogen-containing heterocyclic group” means a 5- to 8-membered monocyclic heterocyclic group that contains one nitrogen atom, and may further contain one or two heteroatoms selected from nitrogen, oxygen, and sulfur. The “monocyclic nitrogen-containing heterocyclic group” is a generic term referring to a “monocyclic nitrogen-containing saturated heterocyclic group” that is a saturated or partially unsaturated ring group and a “monocyclic nitrogen-containing heteroaryl” that is an aromatic ring group. Sulfur or nitrogen which is a ring atom is optionally oxidized to form an oxide or a dioxide. The “monocyclic nitrogen-containing saturated heterocyclic group” is specifically azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, azocanyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl group, or the like. In another embodiment, it is pyrrolidinyl, piperidyl, or piperazinyl group, and in a still another embodiment, pyrrolidinyl group. The “monocyclic nitrogen-containing heteroaryl” is specifically pyridyl, pyrimidinyl, thiazolyl, pyrazolyl, oxadiazolyl group, or the like. In another embodiment, it is pyridyl or pyrimidinyl group, and in a still another embodiment, pyridyl group.


The expression “optionally substituted” means unsubstituted or substituted with 1 to 5 substituents. When plural substituents, these may be the same or different each other.


Some embodiments of compound of formula (I) are shown below.


(1) A compound wherein Z1 is nitrogen atom, and Z2, Z3, Z4, and Z5 are carbon atoms.


(2) A compound wherein Z3 is nitrogen atom, and Z1, Z2, Z4, and Z5 are carbon atoms.


(3) A compound wherein




embedded image


is phenyl group, pyridyl, cyclopropyl, cyclohexenyl, cyclopentenyl, or pyrrolidinyl group, and in another embodiment, phenyl or pyridyl group. (The present ring group is hereinafter referred as ring group A.)


(4) A compound wherein R1, R2, and R3 are each H, lower alkyl, halogen, halogeno-lower alkyl, —CN, or —ORa; in another embodiment, H, lower alkyl, F, Cl, trifluoromethyl, —CN, or —ORa; and in a still another embodiment, H, F, Cl, or —ORa group.


(5) A compound wherein R4, R5, and R6 are each H, lower alkyl, cyclopropyl, halogen, halogeno-lower alkyl, —CN, or —C(O)NRbRc; in another embodiment, H, lower alkyl, F, Cl, halogeno-lower alkyl, —CN, or —C(O)NRbRc; and still in another embodiment, H, lower alkyl, F, Cl, or halogeno-lower alkyl group.


(6) A compound wherein both R7 and R8 are H.


(7) A compound which combines two or more groups described in the above (1) to (6).


Examples of specific embodiments of (7) above include the following compounds.


(8) A compound as described in the aforesaid (3), wherein both R7 and R8 are H.


(9) A compound as described in the aforesaid (3) or (8), wherein R1, R2, and R3 are as described in the aforesaid (4).


(10) A compound as described in any one of the aforesaid (3), (8), (9), wherein R4, R5, and R6 are as described in the aforesaid (5).


(11) A compound as described in the aforesaid (3), wherein Z1 is a nitrogen atom, and Z2, Z3, Z4, and Z5 are carbon atoms.


(12) A compound as described in the aforesaid (3), wherein Z3 is a nitrogen atom, and Z1, Z2, Z4, and Z5 are carbon atoms.


(13) A compound as described in the aforesaid (11) or (12), wherein both R7 and R8 are H.


(14) A compound as described in any one of the aforesaid (11) to (13), wherein R1, R2, and R3 are as described in the aforesaid (4).


(15) A compound as described in any one of the aforesaid (11) to (14), wherein R4, R5, and R6 are as described in (5) above.


(16) A compound wherein Z1 is a nitrogen atom; Z2, Z3, Z4, and Z5 are carbon atoms; the ring group A is phenyl, pyridyl, cyclopropyl, cyclohexenyl, cyclopentenyl, or pyrrolidinyl group; R1, R2, and R3 are each H, lower alkyl, halogen, halogeno-lower alkyl, —CN, or —ORa; R4, R5, and R6 are each H, lower alkyl, cyclopropyl, halogen, halogeno-lower alkyl, —CN, or —C(O)NRbRc; and R7 and R8 are both H.


(17) A compound wherein Z3 is a nitrogen atom; Z1, Z2, Z4, and Z5 are carbon atoms; the ring group A is phenyl, pyridyl, cyclopropyl, cyclohexenyl, cyclopentenyl, or pyrrolidinyl group; R1, R2, and R3 are each H, lower alkyl, halogen, halogeno-lower alkyl, —CN, or —ORa; R4, R5, and R6 are each H, lower alkyl, cyclopropyl, halogen, halogeno-lower alkyl, —CN, or —C(O)NRbRc; and both R7 and R8 are H.


(18) A compound wherein Z1 is a nitrogen atom; Z2, Z3, Z4, and Z5 are carbon atoms; the ring group A is phenyl or pyridyl group; R1, R2, and R3 are each H, F, Cl, or a ORa group; R4, R5, and R6 are each H, lower alkyl, F, Cl, or a halogeno-lower alkyl group; and both R7 and R8 are H.


(19) A compound wherein Z3 is a nitrogen atom; Z1, Z2, Z4, and Z5 are carbon atoms; the ring group A is phenyl or pyridyl group; R1, R2, and R3 are each H, F, Cl, or —ORa group; R4, R5, and R6 are each H, lower alkyl, F, Cl, or a halogeno-lower alkyl group; and both R7 and R8 are H.


(20) A compound or a salt thereof, which is selected from the group consisting of:

  • N-(diaminomethylene)-2-methyl-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide,
  • 1-(2-chloro-6-fluorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,
  • N-(diaminomethylene)-1-(2,6-difluorophenyl)-4-fluoroisoquinoline-7-carboxamide,
  • 1-(2-chloro-4-fluorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,
  • N-(diaminomethylene)-4-methyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxamide,
  • N-(diaminomethylene)-2,3-dimethyl-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide,
  • N-(diaminomethylene)-1-(3,5-difluoropyridin-4-yl)-4-fluoroisoquinoline-7-carboxamide,
  • N-(diaminomethylene-4-fluoro-1-(2-fluoro-6-methoxyphenyl)isoquinoline-7-carboxamide,
  • N-(diaminomethylene)-4-fluoro-1-(2-fluorophenyl)isoquinoline-7-carboxamide,
  • 1-(2-chlorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,
  • 4-chloro-N-(diaminomethylene)-1-(2,6-difluorophenyl)isoquinoline-7-carboxamide,
  • 1-(3-chloro-5-fluoropyridin-4-yl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,
  • N-(diaminomethylene)-1-(2,6-difluorophenyl)-4-methylisoquinoline-7-carboxamide,
  • 1-(3-chloro-5-fluoropyridin-2-yl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,
  • N-(diaminomethylene)-4-(difluoromethyl)-1-(2,6-difluorophenyl)isoquinoline-7-carboxamide,
  • N-(diaminomethylene)-1-(2-fluorophenyl)-4-methylisoquinoline-7-carboxamide, and
  • 4-chloro-N-(diaminomethylene)-1-(2,4-difluorophenyl)isoquinoline-7-carboxamide.


Furthermore, compound of formula (I) may exist as other tautomers, conformational isomers, or optical isomers, depending on the kinds of substituents. In the present specification, compound of formula (I) shall be described in only one form of the isomers, yet the present invention includes such isomers, their isolated forms or their mixtures. For example, among the compounds (I), compounds having lower alkyl as R7 or R8 may exist as isomers having different positions of double bonds and geometrical arrangement in the guanidine moiety. The present invention includes all of these isomers.


Furthermore, pharmaceutically acceptable prodrugs of compound of formula (I) are also included in the present invention. Pharmaceutically acceptable prodrugs refer to compounds which have a group that can be converted into an amino group, OH, CO2H, or the like by solvolysis or under physiological conditions. Examples of groups forming prodrugs include the groups described in “Prog. Med., 5, 2157-2161 (1985), and “Iyakuhin no Kaihatsu (Development of Medicines)” (Hirokawa Publishing company, 1990), vol. 7, Bunshi Sekkei (Molecular Design)”, 163-198.


Furthermore, compound of formula (I) may form an acid addition salt, or may form a salt with a base depending on the kind of substituents, and the salts are included in the present invention as long as they are pharmaceutically acceptable salts. Specifically, examples of these salts include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, aspartic acid, and glutamic acid, salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum, and organic bases such as methylamine, ethylamine, ethanolamine, lysine, and ornithine, and ammonium salts.


In addition, compound of formula (I) and pharmaceutically acceptable salts thereof include hydrates, solvates, and crystal polymorphs. Also, compound of formula (I) and pharmaceutically acceptable salts thereof include the compounds labeled with radioactive or non-radioactive isotopes.


(Production Processes)


Compound of formula (I) and pharmaceutically acceptable salts thereof can be produced by applying known synthetic methods, according to its basic skeleton or kind of substituents. Protection of the functional groups with suitable protecting groups (groups which can be easily converted into the original functional group) may be effective in technical means, depending on the kind of the functional group, in any step from starting materials to intermediates. Examples of functional groups include amino group, hydroxyl group, and carboxyl group, and examples of the protecting group include those described in “Greene's Protective Groups in Organic Synthesis (4th Edition, 2006)”, edited by P. G. M. Wuts and T. W. Greene, which can be selected and used depending on the reaction conditions. In this way, the object compound can be obtained by introducing a protecting group during the reaction, and then, by optionally removing it.


In addition, prodrugs of compound of formula (I) can be produced by introducing a specific group during any step from starting materials to intermediates, in a similar way to the aforementioned protecting groups, or by carrying out further reactions using the obtained compound of formula (I). The reaction can be carried out by employing known methods to a skilled person in the art, such as usual esterification, amidation, and dehydration reactions.


Hereinbelow, representative production processes of compound of formula (I) are described. Each production process can be carried out according to the references cited in the description. Further, production processes of the present invention are not limited to the examples as shown below.


(Production Process 1)



embedded image


(Lv1 Represents —OH or a Leaving Group.)


Compound of formula (I) can be produced by the reaction of a carboxylic acid or a reactive derivative thereof (1) with guanidine (2) or a salt thereof.


The reaction can be carried out by using the carboxylic acid or a reactive derivative thereof (1) and guanidine (2) in equivalent amounts, or guanidine in an excess amount. It can be carried out under cooling to under heating, and preferably at −20° C. to 80° C., in a solvent inert to the reaction, such as aromatic hydrocarbons such as benzene, toluene, xylene, and the like; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like; ethers such as diethylether, tetrahydrofuran (THF), dioxane, dimethoxyethane (DME), and the like; N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP), ethyl acetate, acetonitrile, water, and the like, or a mixtures thereof.


When a carboxylic acid wherein Lv1 is —OH is used as the carboxilic acid or a reactive derivative thereof (1), it is desirable to carry out the reaction in the presence of a condensing agent. In this case, examples of the condensing agent include N,N′-dicyclohexylcarbodiimide (DCC), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (WSC), 1,1′-carbonyldiimidazole (CDI), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), diphenylphosphoryl azide (DPPA), and phosphorous oxychloride. In some cases, it is preferable to further use additive agents (e.g., N-hydroxysuccinimide (HONSu), 1-hydroxybenzotriazole (HOBt) and the like). The condensing agent is usually used in an equivalent amount or excess to the carboxylic acid.


When a reactive derivative of the carboxylic acid wherein Lv1 is a leaving group is used as the carboxylic acid or a reactive derivative thereof (1), acid halides (acid chloride, acid bromide, or the like), acid anhydrides (mixed acid anhydrides obtained by the reaction of the carboxylic acid with phenyl chlorocarbonate, p-toluenesulfonic acid, isovaleric acid, or the like; or symmetric acid anhydrides), active esters (esters which can be prepared from phenol, HOBt, HONSu, or the like; optionally substituted with an electron withdrawing group such as a nitro group, a fluorine atom, and the like), lower alkyl esters, and the like can be exemplified. Each of which can be produced from carboxylic acid using reactions obvious to those skilled in the art. Depending on the kind of the reactives, it is sometimes advantageous for quick progress of the reaction to carry out the reaction in presence of a base (organic bases such as triethylamine, diisopropylethylamine (DIPEA), N-methylmorpholine, pyridine, 4-(N,N-dimethylamino)pyridine, and the like, or inorganic bases such as sodium hydrogen carbonate and the like). Pyridine can also serve as a solvent. Further, when a lower alkyl ester is used as the reactive derivative, it is preferable to carry out the reaction under from room temperature to heating under reflux.


(Production Process 2)




embedded image


(Lv2 represents a leaving group such as pyrazol-1-yl optionally substituted with lower alkyl, or —S-lower alkyl, —O-phenyl, —Br, —Cl, and the like, and R8a represents lower alkyl.)


Compound (Ia) having lower alkyl as R8 among compounds of formula (I) can be produced by reaction of an amidine compound (3) having a leaving group with an amine compound (4).


This reaction can be carried out using compound (3) and compound (4) in equivalent amounts, or in an excess amount of one of them, in which their mixture is stirred under from cooling to heating under reflux, and preferably from 0° C. to 80° C., usually for 0.1 hours to 5 days, in a solvent inert to reaction or without solvent. Examples of solvents used herein are not limited, but include aromatic hydrocarbons, ethers, halogenated hydrocarbons, DMF, DMSO, ethyl acetate, acetonitrile, and a mixture thereof. It is sometimes advantageous for smooth progress of the reaction to carry out the reaction in the presence of organic bases such as triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like, or inorganic bases such as potassium carbonate, sodium carbonate, potassium hydroxide, and the like.


Carboxylic acid or a reactive derivative thereof (1) of the above Production Process 1 can be produced by known methods or any variation thereof. For example, starting compound (1a) can be produced by the reaction route shown below (Production Process of Starting Compound).


(Production Process of Starting Compound)




embedded image


(In the formula, X1 represents halogen, methanesulfonyloxy group, p-toluenesulfonyloxy group, or trifluoromethanesulfonyloxy group, R11 represents a protecting group of carboxyl group such as lower alkyl, benzyl, or the like, and X2 represents an active group such as —B(OH)2, —B(OY)OW, and the like. Here, Y and W are the same or different from each other and represent lower alkyl, or Y and W are combined together to form lower alkylene.)


Compound (1a) can be obtained by coupling reaction of compound (5) and compound (6) to first obtain compound (7), followed by its hydrolysis.


Synthesis of compound (7) is carried out by using a mixture of compound (5) and compound (6) in equivalent amounts or in an excess of one of them, and stirring the mixture under from room temperature to heating under reflux, usually for 0.1 hours to 5 days, in a reaction inert solvent in the presence of a base and palladium catalyst. The present reaction is preferably carried out under an inert gas atmosphere. Examples of solvents used herein include, but not particularly limited to, aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols such as methanol, ethanol, and the like, DMF, DMSO, and mixed solvents thereof. As bases, inorganic bases such as sodium carbonate, potassium carbonate, sodium hydroxide, and the like are preferred. Examples of the palladium catalyst include tetrakis(triphenylphosphine)palladium, dichlorobis(triphenylphosphine)palladium, palladium-1,1′-bis(diphenylphosphino)ferrocene chloride, tris(dibenzylideneacetone)dipalladium, and the like. As palladium ligands, tert-butylphosphine, cyclohexylphosphine, 2-dicyclohexylphosphinobiphenyl derivative, or the like can be used.


The coupling reaction can be carried out with reference to the following documents.


DOCUMENTS



  • A. de Meijere and F. Diederich, “Metal-Catalyzed Cross-Coupling Reactions”, 2nd edition, VCH Publishers Inc., 2004

  • The Chemical Society of Japan, “Courses in Experimental Chemistry (5th edition)” Vol. 13 (2005) (Maruzen)



Subsequently, compound (7) can be subjected to hydrolysis reaction to obtain compound (1a). The hydrolysis reaction can be carried out with reference to “Greene's Protective Groups in Organic Synthesis (4th edition, 2006)” shown above.


(Other Production Processes)


In addition, compounds (5) and (6) described above in (Production Process of Starting Compound) can be produced by known methods or any variation thereof, and for example, they can be produced by the methods described in Preparation Examples below.


Compound of formula (I) prepared in accordance with the aforementioned methods is isolated and purified as a free compound, as a pharmaceutically acceptable salt, hydrate, solvate, or crystalline polymorph thereof. Pharmaceutically acceptable salts of compound of formula (I) can be prepared using salt preparation methods well-known to those skilled in the art.


Isolation and purification are carried out by applying common chemical operations such as extraction, fractional crystallization and fractional chromatography.


A variety of isomers can be produced by selecting their corresponding starting compounds or by separation of isomers using their physicochemical properties differences. For example, optical isomers are obtained by general optical resolution methods of racemic compounds (for example, fractional crystallization of diastereomeric salts obtained from optically active bases or acids; or chiral column chromatography), and also can be prepared from suitable optical active starting compounds.


EXAMPLES

Hereinafter, production processes of compound of formula (I) are described as Examples. In addition, production processes of compounds used as starting compounds are described as Preparation Examples. Production processes of compound of formula (I) are not limited to the production processes of the following specific Examples, but the compounds can be prepared by combining these production processes or known production processes.


Preparation Example 1

A mixture of 4-(2,4,6-trifluorophenyl)quinoline-6-carboxylic acid (118 mg), WSC hydrochloride (112 mg), HOBt (37 mg), and DMF (4 mL) was stirred at room temperature for 5 minutes, and then 3,5-dimethyl-1H-pyrazole-1-carboximidamide nitrate (94 mg) and DIPEA (76 mg) were added thereto, followed by stirring for an additional 24 hours. The reaction mixture was diluted with water, and the precipitate was collected by filtration to obtain N-[1-amino(3,5-dimethyl-1H-pyrazol-1-yl)methylene]-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide (140 mg).


Preparation Example 2

A mixture of methyl 1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (228 mg), a 1M aqueous sodium hydroxide solution (4 mL), THF (3 mL), and ethanol (3 mL) was stirred at room temperature for 24 hours. The reaction mixture was neutralized with 1M hydrochloric acid, and the precipitate was collected by filtration to obtain 1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylic acid hydrochloride (200 mg).


Preparation Example 3

2-Carbamoyl-4-(2,4,6-trifluorophenyl)quinoline-6-carboxylic acid was obtained by the same reaction as in Preparation Example 2 by using methyl 2-cyano-4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate as the starting material.


Preparation Example 4

Under argon gas atmosphere, a mixture of methyl 1-{[(trifluoromethyl)sulfonyl]oxy}isoquinoline-7-carboxylate (250 mg), 2,4,6-trifluorophenylboric acid (184 mg), tetrakis(triphenylphosphine)palladium (22 mg), triethylamine (189 mg), and 1,4-dioxane (15 mL) was heated under stirring in an oil bath at 95° C. for 18 hours. The reaction mixture was returned to room temperature, diluted with water, and then extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (228 mg).


Preparation Example 5

Under argon gas atmosphere, a mixture of methyl 4-bromo-3-chloroquinoline-6-carboxylate (130 mg), 2,4-difluorophenylboric acid (137 mg), a 1,1′-bis(diphenylphosphino)ferrocene palladium (H) dichloride/dichloromethane complex (177 mg), cesium fluoride (197 mg), 1,4-dioxane (8 mL), and water (2 mL) was heated under stirring in an oil bath at 100° C. for one day. The reaction mixture was returned to room temperature, and water was added, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 3-chloro-4-(2,4-difluorophenyl)quinoline-6-carboxylate (100 mg).


Preparation Example 6

Under argon gas atmosphere, a mixture of methyl 4-bromo-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (292 mg), 2,4,6-trivinylboroxin-pyridine complex (89 mg), palladium acetate (19 mg), tricyclohexylphosphine (45 mg), tripotassium phosphate (280 mg), toluene (7 mL), and water (0.5 mL) was heated under stirring in an oil bath at 100° C. for 12 hours. The reaction mixture was returned to room temperature, diluted with water and ethyl acetate, and then the insoluble materials were separated by filtration. The filtrate was extracted with ethyl acetate, and the organic layer was concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 1-(2,4,6-trifluorophenyl)-4-vinylisoquinoline-7-carboxylate (180 mg).


Preparation Example 7

Under argon gas atmosphere, a mixture of methyl 4-bromo-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (160 mg), trimethylboroxin (117 mg), tetrakis(triphenylphosphine)palladium (23 mg), 2M aqueous sodium carbonate solution (1 mL), and 1,4-dioxane (5 mL) was heated under stirring in an oil bath at 100° C. for 4 hours. The reaction mixture was returned to room temperature and diluted with ethyl acetate, and then the insoluble materials were separated by filtration through Celite. The filtrate was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain 4-methyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylic acid (95 mg).


Preparation Example 8

Under argon gas atmosphere, a mixture of ethyl 5-bromoquinoline-3-carboxylate (113 mg), 2,4,6-trifluorophenylboric acid (106 mg), bis(tri-t-butylphosphine)palladium (41 mg), cesium fluoride (123 mg), silver oxide (112 mg), and DMF (2 mL) was heated under stirring in an oil bath at 100° C. for 15 hours. The reaction liquid was returned to room temperature, diluted with water, and then extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain ethyl 5-(2,4,6-trifluorophenyl)quinoline-3-carboxylate (60 mg).


Preparation Example 9

Under argon gas atmosphere, n-butyllithium (1.6 M THF solution, 0.7 mL) was added dropwise to a mixture of 3,5-difluoropyridine (123 mg) and THF (3 mL) at −78° C., followed by stirring at the same temperature for one hour. Then, zinc chloride (146 mg) was added, and stirred for an additional hour. Methyl 4-chloro-1-{[(trifluoromethyl)sulfonyl]oxy}isoquinoline-7-carboxylate (330 mg) and tetrakis(triphenylphosphine)palladium (206 mg) were added thereto, followed by heating under stirring in an oil bath at 60° C. for 3 hours. The reaction mixture was concentrated under reduced pressure and purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-chloro-1-(3,5-difluoropyridin-4-yl)isoquinoline-7-carboxylate (62 mg).


Preparation Example 10

Under argon gas atmosphere, n-butyllithium (1.6 M THF solution, 1.3 mL) was added dropwise to a mixture of 3,5-difluoropyridine (238 mg) and THF (4 mL) at −78° C., followed by stirring at the same temperature for one hour. Then, zinc chloride (0.5 M THF solution, 3.8 mL) was slowly added stirried at the same temperature for 30 minutes and further for an additional hour at room temperature. Tris(dibenzylideneacetone)dipalladium (73 mg), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (148 mg), and ethyl 2,3-dimethyl-4-{[(trifluoromethyl)sulfonyl]oxy}quinoline-6-carboxylate (300 mg), were added to the reaction mixture and heated under stirring in an oil bath at 70° C. for 15 hours. The reaction mixture was returned to room temperature, and the insoluble materials were separated by filtration. Then, the precipitate was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain ethyl 4-(3,5-difluoropyridin-4-yl)-2,3-dimethylquinoline-6-carboxylate (51 mg).


Preparation Example 11

Trifluoromethanesulfonic anhydride (2.1 g) was added to a mixture of methyl 1-hydroxyisoquinoline-7-carboxylate (1.3 g), pyridine (587 mg), and dichloromethane (40 mL), followed by stirring at room temperature for 18 hours. The reaction mixture was diluted with water, extracted with chloroform, and the organic layer was concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (chloroform/methanol) to obtain methyl 1-{[(trifluoromethyl)sulfonyl]oxy}isoquinoline-7-carboxylate (1.9 g).


Preparation Example 12

Boron tribromide (1M dichloromethane solution, 2.5 mL) was added to a mixture of methyl 4-fluoro-1-(2-fluoro-6-methoxyphenyl)isoquinoline-7-carboxylate (270 mg) and dichloromethane (3 mL) under ice-cooling, and stirred at room temperature for 16 hours. The reaction mixture was diluted with water, and the precipitate was collected by filtration to obtain 4-fluoro-1-(2-fluoro-6-hydroxyphenyl)isoquinoline-7-carboxylic acid (240 mg).


Preparation Example 13

m-Chloroperbenzoic acid (425 mg) was added to a mixture of methyl 4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate (710 mg) and dichloromethane (20 mL), followed by stirring at room temperature for 3 days. The reaction mixture was diluted with aqueous sodium thiosulfate solution, and extracted with chloroform. The organic layer was washed with water, dried, and concentrated under reduced pressure to obtain methyl 4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate 1-oxide (680 mg).


Preparation Example 14

A mixture of methyl 3,4-dichloroquinoline-6-carboxylate (100 mg), pyrrolidine (33 mg), and NMP (2 mL) was heated under stirring at 180° C. for 10 minutes under microwave irradiation. The reaction mixture was diluted with water, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 3-chloro-4-(pyrrolidin-1-yl)quinoline-6-carboxylate (40 mg).


Preparation Example 15

Sodium borohydride (17 mg) was added to a mixture of methyl 4-formyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (150 mg) and methanol (10 mL) under ice-cooling, followed by stirring at room temperature for 10 minutes. The reaction mixture was diluted with water, and extracted with ethyl acetate. The organic layer was washed with water, dried, and then concentrated under reduced pressure to obtain methyl 4-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (140 mg).


Preparation Example 16

Osmium tetraoxide (2.5% isobutanol solution, 0.05 mL), sodium periodate (280 mg), and water (4 mL) were added to a mixture of methyl 1-(2,4,6-trifluorophenyl)-4-vinylisoquinoline-7-carboxylate (180 mg) and THF (4 mL), followed by stirring at room temperature for 12 hours. The reaction mixture was diluted with an aqueous sodium sulfite solution, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure and purified by silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-formyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (153 mg).


Preparation Example 17

Under hydrogen gas atmosphere at 1 atm, a mixture of methyl 1-(2,6-difluorophenyl)-4-(prop-1-en-2-yl)isoquinoline-7-carboxylate (85 mg), 10% palladium-active carbon (20 mg), and methanol was stirred at room temperature for 4 days. The insoluble materials were separated by filtration, and then the filtrate was concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (chloroform) to obtain methyl 1-(2,6-difluorophenyl)-4-isopropyl isoquinoline-7-carboxylate (72 mg).


Preparation Example 18

A mixture of methyl 4-bromo-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (66 mg), zinc cyanide (content 60%, 21 mg), tris(dibenzylideneacetone)dipalladium (0) (14 mg), 1,1′-bis(diphenylphosphino)ferrocene (17 mg), and N-methyl-2-pyrrolidone (3 mL) was heated under stirring in an oil bath at 150° C. for 3 hours. The reaction mixture was returned to room temperature, diluted with water and ethyl acetate, and then the insoluble materials were separated by filtration. The filtrate was subjected to liquid separation, and the organic layer was concentrated under reduced pressure. Then, the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-cyano-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (44 mg).


Preparation Example 19

A mixture of methyl-1-oxide 4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate (540 mg), trimethylsilyl cyanide (530 mg), triethylamine (607 mg), dichloromethane (10 mL), and acetonitrile (20 mL) was heated under reflux for one day. The reaction mixture was returned to room temperature, diluted with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 2-cyano-4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate (460 mg).


Preparation Example 20

A mixture of methyl 1-hydroxy-3-methylisoquinoline-7-carboxylate (120 mg), Selectfluor (registered trademark) (215 mg), acetonitrile (2 mL), and methanol (2 mL) was stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with water. Then, the precipitate was collected by filtration to obtain methyl 4-fluoro-1-hydroxy-3-methylisoquinoline-7-carboxylate (55 mg).


Preparation Example 21

DEOXO-FLUOR (registered trademark) (240 mg) was added dropwise to a mixture of methyl 1-(2,6-difluorophenyl)-4-formylisoquinoline-7-carboxylate (96 mg) and dichloromethane (5 mL) at 0° C., and stirred at room temperature for one hour. The reaction mixture was diluted with saturated aqueous sodium bicarbonate, and extracted with chloroform. The organic layer was concentrated under reduced pressure and purified by silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-(difluoromethyl)-1-(2,6-difluorophenyl)isoquinoline-7-carboxylate (80 mg).


Preparation Example 22

A mixture of methyl 4-hydroxyquinoline-6-carboxylate (2.07 g), N-chlorosuccinimide (1.36 g), and acetic acid (56 mL) was stirred at room temperature for one day. The reaction mixture was diluted with water, and then, the precipitate was collected by filtration to obtain methyl 3-chloro-4-hydroxyquinoline-6-carboxylate (2.13 g).


Preparation Example 23

Methyl 4-chloro-1-hydroxyisoquinoline-7-carboxylate was prepared by the same reaction as in Preparation Example 22 using methyl 1-hydroxyisoquinoline-7-carboxylate as the starting material.


Preparation Example 24

A mixture of ethyl 3-chloro-4-hydroxy-2-methylquinoline-6-carboxylate (629 mg) and phosphoryl chloride (2 mL) was stirred in an oil bath at 100° C. for 18 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with water, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain ethyl 3,4-dichloro-2-methylquinoline-6-carboxylate (454 mg).


Preparation Example 25

A mixture of methyl 4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate 1-oxide (1.3 g) and phosphoryl chloride (10 mL) was heated under stirring in an oil bath at 100° C. for 2 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with water, and then extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 2-chloro-4-(2,4,6-trifluorophenyl)quinoline-6-carboxylate (370 mg).


Preparation Example 26

A mixture of bromine (940 mg) and acetic acid (10 mL) was added dropwise to a mixture of methyl 1-hydroxyisoquinoline-7-carboxylate (1.2 g) and acetic acid (50 mL) and stirred at room temperature for 30 minutes. The reaction mixture was diluted with water, and the precipitate was collected by filtration to obtain methyl 4-bromo-1-hydroxyisoquinoline-7-carboxylate (1.4 g).


Preparation Example 27

A mixture of methyl 3-chloro-4-hydroxyquinoline-6-carboxylate (600 mg) and phosphoryl bromide (868 mg) was heated under stirring in an oil bath at 130° C. for 6 hours. Ice-water was added, followed by neutralization with saturated aqueous sodium bicarbonate and extraction with ethyl acetate. The organic layer was washed with water, dried, and concentrated under reduced pressure to obtain methyl 4-bromo-3-chloroquinoline-6-carboxylate (426 mg).


Preparation Example 28

To a mixture of methyl 1-hydroxyisoquinoline-7-carboxylate (1.0 g) and pyridine (40 mL) was added iodine (1.2 g), and stirred at room temperature for 16 hours. The reaction mixture was diluted with saturated aqueous sodium bicarbonate and a 5% aqueous sodium thiosulfate solution. Then, the precipitate was collected by filtration to obtain methyl 1-hydroxy-4-iodoisoquinoline-7-carboxylate (1.1 g).


Preparation Example 29

To a mixture of methyl 4-oxo-1,4-dihydroquinoline-6-carboxylate (1.1 g) and acetic acid (30 mL) was added N-iodosuccinimide (1.1 g), followed by stirring at room temperature for one day. The reaction mixture was diluted with water, and the precipitate was collected by filtration to obtain methyl 3-iodo-4-oxo-1,4-dihydroquinoline-6-carboxylate (1.8 g).


Preparation Example 30

Methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1.7 g) and copper(I) iodide (174 mg) were added to a mixture of methyl 3-iodo-4-oxo-1,4-dihydroquinoline-6-carboxylate (1.0 g) and DMF (20 mL), followed by heating under stirring in an oil bath at 100° C. for 5 hours. The reaction mixture was returned to room temperature, concentrated under reduced pressure, and then the resulting residue was purified under silica gel column chromatography (chloroform/methanol) to obtain methyl 4-oxo-3-(trifluoromethyl)-1,4-dihydroquinoline-6-carboxylate (228 mg).


Preparation Example 31

A mixture of methyl 3-methyl-1-oxo-1H-isochromene-7-carboxylate (1.0 g), 29% aqueous ammonia solution (30 mL) and THF (30 mL) was stirred at room temperature for 8 hours. The reaction mixture was neutralized with hydrochloric acid, and the precipitate was collected by filtration to obtain methyl 1-hydroxy-3-methylisoquinoline-7-carboxylate (390 mg).


Preparation Example 32

Concentrated sulfuric acid (3 mL) was added to a mixture of sodium 3-methyl-1-oxo-1H-isochromene-7-carboxylate (1.69 g) and methanol (50 mL), and heated under stirring in an oil bath at 60° C. for 2 days. The reaction mixture was returned to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water, dried, and concentrated under reduced pressure to obtain methyl 3-methyl-1-oxo-1H-isochromene-7-carboxylate (1.0 g).


Preparation Example 33

Under oxygen atmosphere, a mixture of 4-allyl isophthalic acid (500 mg), bis(acetonitrile)dichloropalladium (629 mg), sodium carbonate (514 mg), and THF (30 mL) was stirred at room temperature for 4 hours. The insoluble material of the reaction mixture was separated by filtration, and the filtrate was concentrated under reduced pressure. A mixture of the resulting residue and DMF (5 mL) was diluted with 1M hydrochloric acid, and the precipitate was collected by filtration to obtain 3-methyl-1-oxo-1H-isochromene-7-carboxylic acid (112 mg).


Preparation Example 34

Under argon gas atmosphere, a mixture of dimethyl 4-bromoisophthalate (5.0 g), allyl tributyl tin (6.7 g), tetrakis(triphenylphosphine)palladium (1.1 g), and toluene (100 mL) was heated under reflux for 20 hours. The reaction mixture was returned to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain dimethyl 4-allyl isophthalic acid (3.1 g).


Preparation Example 35

A mixture of 4-{[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl]amino}-3-methylbenzoic acid (10.1 g) and diphenyl ether (101 mL) was heated under stirring in an oil bath at 280° C. for 2 hours. The reaction mixture was returned to room temperature, diluted with petroleum ether and the precipitate was collected by filtration to obtain 4-hydroxy-8-methylquinoline-6-carboxylic acid (6.7 g).


Preparation Example 36

A mixture of 4-amino-3-methylbenzoic acid (7.3 g), Meldrum's acid (7.3 g), methyl orthoformate (5.6 g) and methanol (30 mL) was heated under stirring in an oil bath at 60° C. for 5 hours. The reaction mixture was returned to room temperature, diluted with ethyl acetate and the precipitate was collected by filtration to obtain 4-{[(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl]amino}-3-methylbenzoic acid (10.1 g).


Preparation Example 37

A mixture of phosphorus pentoxide (37 g) and phosphoric acid (46 g) was heated under stirring in an oil bath at 140° C., and methyl 4-amino-3-methylbenzoate (3.0 g) and ethyl acetoacetate (2.8 g) were added thereto, followed by heating under stirring for an additional 2 hours. The reaction mixture was cooled to 60° C., poured into water, and neutralized with a 29% aqueous ammonia solution, and the precipitate was collected by filtration to obtain methyl 2,8-dimethyl-4-oxo-1,4-dihydroquinoline-6-carboxylate (1.8 g).


Preparation Example 38

A mixed liquid of 7-bromo-4-fluoroisoquinolin-1-ol hydrochloride (3.0 g), palladium (II) acetate (484 mg), 1,1′-bis(diphenylphosphino)ferrocene (1.2 g), triethylamine (4.4 g), NMP (60 mL), and methanol (60 mL) was stirred at room temperature for 15 minutes while carbon monoxide gas was passed therethrough. The reaction was further heated under stirring in an oil bath at 80° C. for 16 hours under a carbon monoxide gas atmosphere at 1 atm. The reaction mixture was returned to room temperature, the insoluble materials were separated by filtration, and then the precipitate was concentrated under reduced pressure. The resulting residue was diluted with water, and then the precipitate was collected by filtration to obtain methyl 4-fluoro-1-hydroxyisoquinoline-7-carboxylate (2.3 g).


Preparation Example 39

A mixture of 2-bromo-1-chloro-3,5-difluorobenzene (800 mg), bis(pinacolato)diborone (1.1 g), bis(triphenylphosphine)palladium chloride (123 mg), triphenylphosphine (92 mg), potassium acetate (1.0 g), and 1,4-dioxane (24 mL) was heated under stirring in an oil bath at 100° C. for 18 hours. The reaction mixture was returned to room temperature, the insoluble materials were separated by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain 2-(2-chloro-4,6-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (242 mg).


Preparation Example 521

Under argon gas atmosphere, a mixture of methyl 4-bromo-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (150 mg), ethylboronic acid (84 mg), tetrakis(triphenylphosphine)palladium (44 mg), tripotassium phosphate (241 mg), toluene (5 mL), and water (0.3 mL) was heated under stirring in an oil bath at 100° C. for one day. The reaction mixture was returned to room temperature, and diluted with water and ethyl acetate, and then the insoluble matter was separated by filtration. The filtrate was extracted with ethyl acetate, and the organic layer was concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-ethyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (71 mg).


Preparation Example 522

A mixture of methyl 4-chloro-1-(3-chloro-2-hydroxyphenyl)isoquinoline-7-carboxylate (150 mg), potassium carbonate (119 mg), iodomethane (245 mg), and DMF (3 mL) was stirred at room temperature for one day. The reaction mixture was diluted with water, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 4-chloro-1-(3-chloro-2-methoxyphenyl)isoquinoline-7-carboxylate (130 mg).


Preparation Example 523

Tetrabutylammonium fluoride (1M THF solution, 0.35 mL) was added to a mixture of methyl 1-[3,5-difluoro-4-(trimethylsilyl)pyridin-2-yl]-4-fluoroisoquinoline-7-carboxylate and THF (1.8 mL), and stirred at room temperature overnight. The reaction mixture was diluted with water, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried, and concentrated under reduced pressure. The resulting residue was purified under silica gel column chromatography (hexane/ethyl acetate) to obtain methyl 1-(3,5-difluoropyridin-2-yl)-4-fluoroisoquinoline-7-carboxylate (55 mg).


The compounds of Preparation Examples shown in Tables below were prepared using the respective corresponding starting materials in the same manner as the methods of Preparation Examples above. In addition, the structural formulae, the physicochemical data, and the production methods for the compounds of Preparation Examples are shown in Tables below.


Example 1

A mixture of 1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylic acid hydrochloride (200 mg), CDI (143 mg) and DMF (6 mL) was heated under stirring in an oil bath at 60° C. for 30 minutes. Then, the reaction mixture was returned to room temperature, and guanidine carbonate (265 mg) was added thereto, followed by stirring at room temperature for additional 20 hours. The reaction mixture was diluted with saturated aqueous sodium bicarbonate, extracted with ethyl acetate, and the organic layer was washed with water, dried, and concentrated under reduced pressure. The resulting residue was purified under NH silica gel column chromatography (chloroform/methanol=100:0-20:1), and formed into its salt with 4M hydrogen chloride/ethyl acetate solution to obtain N-(diaminomethylene)-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxamide dihydrochloride (232 mg).


Example 2

A mixture of guanidine hydrochloride (374 mg), sodium methoxide (212 mg), and methanol (10 mL) was stirred at room temperature for one hour. The reaction mixture was concentrated under reduced pressure, and a mixture of methyl 4-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxylate (136 mg) and NMP (10 mL) was added thereto, followed by heating and stirring in an oil bath at 120° C. for 5 hours. The reaction mixture was returned to room temperature, diluted with water, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under NH silica gel column chromatography (chloroform/methanol=100:0-90:10). Then, ethanol and fumaric acid were added thereto, and the precipitate was collected by filtration to obtain N-(diaminomethylene)-4-(hydroxymethyl)-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxamide fumarate (46 mg).


Example 3

A mixture of N-[1-amino(3,5-dimethyl-1H-pyrazol-1-yl)methylene]-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide (73 mg) and methylamine (40% methanol solution, 32 mg) was stirred at room temperature for 20 hours. The reaction mixture was diluted with saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified under silica gel column chromatography (chloroform/methanol=20:1), and formed into its salt with 4M hydrogen chloride/1,4-dioxane solution to obtain N-[1-amino(methylamino)methylene]-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide dihydrochloride.


The compounds of Examples 4 to 223 and 225 to 251 were prepared using the corresponding starting materials in the same manner as Example 1, and the compound of Example 224 was prepared using the corresponding starting materials in the same manner as Example 2. The structural formulae and the physicochemical data of the compounds of Examples are shown in Tables below.


The following abbreviations are used in the tables below.


PEx: Preparation Example number, Ex: Example number, Str: structural formula, Dat: physicochemical data (ESI+: ESI-MS[M+H]+ or ESI-MS[M]+; FAB+: FAB-MS[M+H]+ or FAB-MS[M]+; EI+: EI[M]+; A/E+: APCI/ESI-MS[M+H]+ or APCI/ESI-MS[M]+ (APCI/ESI means simultaneous measurement of APCI and ESI); A/E−: APCI/ESI-MS[M−H] (APCI/ESI means simultaneous measurement of APCI and ESI); NMR: δ (ppm) of peaks by 1HNMR in CDCl3 or DMSO-d6); Sal: salt (Blank or no description represents the free form, and the numeral present before the acidic ingredient represents a molar ratio. For example, when 2HCl is described shows that the compound is dihydrochloride); Me: methyl, Et: ethyl, iPr: isopropyl, cPr: cyclopropyl, tBu: tert-butyl, Tf: trifluoromethanesulfonyl, Fum: fumaric acid, Syn: production process (the numeral shows that the compound was produced using the corresponding starting material in the same manner as in the compound having the number as its Preparation Example number), ND: Not Determined.










TABLE 1





PEx
Str







 1


embedded image







 2


embedded image







 3


embedded image







 4


embedded image







 5


embedded image







 6


embedded image







 7


embedded image







 8


embedded image







 9


embedded image







10


embedded image







11


embedded image







12


embedded image







13


embedded image





















TABLE 2







PEx
Str









14


embedded image









15


embedded image









16


embedded image









17


embedded image









18


embedded image









19


embedded image









20


embedded image









21


embedded image









22


embedded image









23


embedded image









24


embedded image









25


embedded image









26


embedded image









27


embedded image




















TABLE 3





PEx
Str







28


embedded image







29


embedded image







30


embedded image







31


embedded image







32


embedded image







33


embedded image







34


embedded image







35


embedded image







36


embedded image







37


embedded image







38


embedded image







39


embedded image







40


embedded image







41


embedded image







42


embedded image







43


embedded image







44


embedded image





















TABLE 4







PEx
Str









45


embedded image









46


embedded image









47


embedded image









48


embedded image









49


embedded image









50


embedded image









51


embedded image









52


embedded image









53


embedded image









54


embedded image









55


embedded image









56


embedded image









57


embedded image









58


embedded image






















TABLE 5







PEx
Str









59


embedded image









60


embedded image









61


embedded image









62


embedded image









63


embedded image









64


embedded image









65


embedded image









66


embedded image





67


embedded image









68


embedded image









69


embedded image









70


embedded image









71


embedded image









72


embedded image





















TABLE 6






PEx
Str








73


embedded image








74


embedded image








75


embedded image








76


embedded image








77


embedded image








78


embedded image








79


embedded image








80


embedded image








81


embedded image








82


embedded image








83


embedded image








84


embedded image








85


embedded image








86


embedded image




















TABLE 7






PEx
Str


















87


embedded image








88


embedded image








89


embedded image








90


embedded image








91


embedded image








92


embedded image








93


embedded image








94


embedded image








95


embedded image








96


embedded image








97


embedded image








98


embedded image








99


embedded image








100


embedded image





















TABLE 8







PEx
Str









101


embedded image









102


embedded image









103


embedded image









104


embedded image









105


embedded image









106


embedded image









107


embedded image









108


embedded image









109


embedded image









110


embedded image









111


embedded image









112


embedded image









113


embedded image









114


embedded image






















TABLE 9







PEx
Str









115


embedded image









116


embedded image









117


embedded image









118


embedded image









119


embedded image









120


embedded image









121


embedded image









122


embedded image









123


embedded image









124


embedded image









125


embedded image









126


embedded image









127


embedded image









128


embedded image






















TABLE 10







PEx
Str









129


embedded image









130


embedded image









131


embedded image









132


embedded image









133


embedded image









134


embedded image









135


embedded image









136


embedded image









137


embedded image









138


embedded image









139


embedded image









140


embedded image









141


embedded image









142


embedded image






















TABLE 11







PEx
Str









143


embedded image









144


embedded image









145


embedded image









146


embedded image









147


embedded image









148


embedded image









149


embedded image









150


embedded image









151


embedded image









152


embedded image









153


embedded image









154


embedded image









155


embedded image









156


embedded image






















TABLE 12







PEx
Str









157


embedded image









158


embedded image









159


embedded image









160


embedded image









161


embedded image









162


embedded image









163


embedded image









164


embedded image









165


embedded image









166


embedded image









167


embedded image









168


embedded image









169


embedded image









170


embedded image






















TABLE 13







PEx
Str









171


embedded image









172


embedded image









173


embedded image









174


embedded image









175


embedded image









176


embedded image









177


embedded image









178


embedded image









179


embedded image









180


embedded image









181


embedded image









182


embedded image









183


embedded image









184


embedded image






















TABLE 14







PEx
Str









185


embedded image









186


embedded image









187


embedded image









188


embedded image









189


embedded image









190


embedded image









191


embedded image









192


embedded image









193


embedded image









194


embedded image









195


embedded image









196


embedded image









197


embedded image









198


embedded image






















TABLE 15







PEx
Str









199


embedded image









200


embedded image









201


embedded image









202


embedded image









203


embedded image









204


embedded image









205


embedded image









206


embedded image









207


embedded image









208


embedded image









209


embedded image









210


embedded image









211


embedded image









212


embedded image






















TABLE 16







PEx
Str









213


embedded image









214


embedded image









215


embedded image









216


embedded image









217


embedded image









218


embedded image









219


embedded image









220


embedded image









221


embedded image









222


embedded image









223


embedded image









224


embedded image









225


embedded image






















TABLE 17







PEx
Str









226


embedded image









227


embedded image









228


embedded image









229


embedded image









230


embedded image









231


embedded image









232


embedded image









233


embedded image









234


embedded image









235


embedded image









236


embedded image









237


embedded image









238


embedded image






















TABLE 18







PEx
Str









239


embedded image









240


embedded image









241


embedded image









242


embedded image









243


embedded image









244


embedded image









245


embedded image









246


embedded image









247


embedded image









248


embedded image









249


embedded image









250


embedded image









251


embedded image






















TABLE 19







PEx
Str









252


embedded image









253


embedded image









254


embedded image









255


embedded image









256


embedded image









257


embedded image









258


embedded image









259


embedded image









260


embedded image









261


embedded image









262


embedded image









263


embedded image









264


embedded image






















TABLE 20







PEx
Str









265


embedded image









266


embedded image









267


embedded image









268


embedded image









269


embedded image









270


embedded image









271


embedded image









272


embedded image









273


embedded image









274


embedded image









275


embedded image









276


embedded image









277


embedded image






















TABLE 21







PEx
Str









278


embedded image









279


embedded image









280


embedded image









281


embedded image









282


embedded image









283


embedded image









284


embedded image









285


embedded image









286


embedded image









287


embedded image









288


embedded image









289


embedded image









290


embedded image






















TABLE 22







PEx
Str









291


embedded image









292


embedded image









293


embedded image









294


embedded image









295


embedded image









296


embedded image









297


embedded image









298


embedded image









299


embedded image









300


embedded image









301


embedded image









302


embedded image









303


embedded image









304


embedded image





















TABLE 23






PEx
Str








305


embedded image








306


embedded image








307


embedded image








308


embedded image








309


embedded image








310


embedded image








311


embedded image








312


embedded image








313


embedded image








314


embedded image








315


embedded image








316


embedded image








317


embedded image








318


embedded image




















TABLE 24






PEx
Str








319


embedded image








320


embedded image








321


embedded image








322


embedded image








323


embedded image








324


embedded image








325


embedded image








326


embedded image








327


embedded image








328


embedded image








329


embedded image








330


embedded image




















TABLE 25






PEx
Str








331


embedded image








332


embedded image








333


embedded image








334


embedded image








335


embedded image








336


embedded image








337


embedded image








338


embedded image








339


embedded image








340


embedded image








341


embedded image








342


embedded image








343


embedded image








344


embedded image




















TABLE 26






PEx
Str








345


embedded image








346


embedded image








347


embedded image








348


embedded image








349


embedded image








350


embedded image








351


embedded image








352


embedded image








353


embedded image








354


embedded image








355


embedded image








356


embedded image








357


embedded image




















TABLE 27






PEx
Str








358


embedded image








359


embedded image








360


embedded image








361


embedded image








362


embedded image








363


embedded image








364


embedded image








365


embedded image








366


embedded image








367


embedded image








368


embedded image








369


embedded image








370


embedded image




















TABLE 28






PEx
Str








371


embedded image








372


embedded image








373


embedded image








374


embedded image








375


embedded image








376


embedded image








377


embedded image








378


embedded image








379


embedded image








380


embedded image








381


embedded image








382


embedded image




















TABLE 29






PEx
Str








383


embedded image








384


embedded image








385


embedded image








386


embedded image








387


embedded image








388


embedded image








389


embedded image








390


embedded image








391


embedded image








392


embedded image








393


embedded image








394


embedded image








395


embedded image




















TABLE 30






PEx
Str








396


embedded image








397


embedded image








398


embedded image








399


embedded image








400


embedded image








401


embedded image








402


embedded image








403


embedded image








404


embedded image








405


embedded image








406


embedded image








407


embedded image




















TABLE 31






PEx
Str








408


embedded image








409


embedded image








410


embedded image








411


embedded image








412


embedded image








413


embedded image








414


embedded image








415


embedded image








416


embedded image








417


embedded image








418


embedded image








419


embedded image




















TABLE 32






PEx
Str








420


embedded image








421


embedded image








422


embedded image








423


embedded image








424


embedded image








425


embedded image








426


embedded image








427


embedded image








428


embedded image








429


embedded image








430


embedded image








431


embedded image








432


embedded image




















TABLE 33






PEx
Str








433


embedded image








434


embedded image








435


embedded image








436


embedded image








437


embedded image








438


embedded image








439


embedded image








440


embedded image








441


embedded image








442


embedded image








443


embedded image








444


embedded image




















TABLE 34






PEx
Str








445


embedded image








446


embedded image








447


embedded image








448


embedded image








449


embedded image








450


embedded image








451


embedded image








452


embedded image








453


embedded image








454


embedded image








455


embedded image








456


embedded image




















TABLE 35






PEx
Str








457


embedded image








458


embedded image








459


embedded image








460


embedded image








461


embedded image








462


embedded image








463


embedded image








464


embedded image








465


embedded image








466


embedded image








467


embedded image








468


embedded image








469


embedded image




















TABLE 36






PEx
Str








470


embedded image








471


embedded image








472


embedded image








473


embedded image








474


embedded image








475


embedded image








476


embedded image








477


embedded image








478


embedded image








479


embedded image








480


embedded image








481


embedded image




















TABLE 37






PEx
Str








482


embedded image








483


embedded image








484


embedded image








485


embedded image








486


embedded image








487


embedded image








488


embedded image








489


embedded image








490


embedded image








491


embedded image








492


embedded image








493


embedded image



















TABLE 38





PEx
Str







494


embedded image







495


embedded image







496


embedded image







497


embedded image







498


embedded image







499


embedded image







500


embedded image







501


embedded image







502


embedded image







503


embedded image







504


embedded image







505


embedded image



















TABLE 39





PEx
Str







506


embedded image







507


embedded image







508


embedded image







509


embedded image







510


embedded image







511


embedded image







512


embedded image







513


embedded image







514


embedded image







515


embedded image







516


embedded image







517


embedded image



















TABLE 40





PEx
Str







518


embedded image







519


embedded image







520


embedded image






















TABLE 41







PEx
Syn
Dat




















1
1
A/E+: 424



2
2
ESI+: 304



3
3
ESI+: 361



4
4
ESI+: 318



5
5
ESI+: 334



6
6
A/E+: 344



7
7
ESI+: 318



8
8
A/E+: 332



9
9
A/E+: 335



10
10
A/E+: 343



11
11
A/E+: 336



12
12
ESI+: 302



13
13
ESI+: 334



14
14
A/E+: 291, 293



15
15
ESI+: 348



16
16
ESI+: 346



17
17
ESI+: 342



18
18
A/E+: 342



19
19
ESI+: 343



20
20
A/E+: 236



21
21
ESI+: 350



22
22
A/E+: 238



23
23
ESI+: 237



24
24
A/E+: 284, 286



25
25
A/E+: 352



26
26
FAB+: 282, 284



27
27
ESI+: 300, 302



28
28
ESI+: 329



29
29
A/E+: 330



30
30
A/E+: 272



31
31
A/E+: 218



32
32
A/E+: 219



33
33
A/E+: 205



34
34
A/E+: 235



35
35
ESI+: 204



36
36
A/E−: 304



37
37
A/E+: 232



38
38
A/E+: 222



39
39
EI+: 274



40
11
A/E+: 336



41
4
EI+: 263



42
4
EI+: 317



43
2
ESI+: 250



44
2
ESI+: 304



45
4
EI+: 263



46
4
EI+: 317



47
2
ESI+: 250



48
2
ESI+: 304



49
11
ESI+: 364



50
4
ESI+: 346



51
2
ESI+: 318



52
4
ESI+: 264



53
2
ESI+: 250



54
4
A/E+: 344



55
2
ESI+: 316



56
4
ESI+: 332



57
4
ESI+: 332



58
4
ESI+: 316



59
4
ESI+: 289



60
2
ESI+: 318



61
2
ESI+: 318



62
2
ESI+: 302



63
2
ESI+: 275



64
4
EI+: 334



65
2
EI+: 320



66
4
EI+: 333



67
4
ESI+: 316



68
4
ESI+: 316



69
2
ESI+: 320



70
2
ESI+: 302



71
2
ESI+: 302



72
38
A/E+: 218



73
11
A/E+: 350



74
4
EI+: 277



75
4
EI+: 331



76
4
ESI+: 332



77
4
ESI+: 332



78
2
ESI+: 264



79
2
ESI+: 318



80
2
ESI+: 318



81
2
ESI+: 318



82
4
ESI+: 316



83
4
ESI+: 332



84
4
ESI+: 316



85
4
EI+: 333



86
4
EI+: 315



87
4
EI+: 315



88
2
ESI+: 320



89
2
ESI+: 302



90
2
ESI+: 302



91
2
A/E+: 302



92
2
A/E+: 318



93
2
A/E+: 302



94
4
ESI+: 332



95
4
ESI+: 332



96
4
ESI+: 289



97
4
A/E+: 348



98
4
A/E+: 346



99
4
A/E+: 366



100
2
A/E+: 318



101
2
A/E+: 318



102
2
A/E+: 275



103
2
ESI+: 334



104
2
ESI+: 332



105
2
ESI+: 352



106
4
ESI+: 350



107
4
ESI+: 400



108
2
ESI+: 336



109
2
ESI+: 386



110
4
ESI+: 323



111
4
ESI+: 350





















TABLE 42







PEx
Syn
Dat




















112
2
ESI+: 336



113
2
A/E−: 307



114
4
A/E+: 314



115
4
A/E+: 314



116
4
ESI+: 289



117
4
ESI+: 350



118
2
ESI+: 300



119
2
ESI+: 300



120
2
ESI+: 275



121
2
ESI+: 336



122
4
ESI+: 294



123
4
ESI+: 319



124
2
ESI+: 280



125
2
ESI+: 305



126
4
EI+: 349



127
4
EI+: 349



128
36
ND



129
2
ESI+: 336



130
2
ESI+: 336



131
32
A/E+: 218



132
35
ND



133
32
A/E+: 238



134
11
FAB+: 350



135
2
ESI+: 320



136
4
ESI+: 332



137
4
A/E+: 330



138
2
A/E+: 318



139
11
ND



140
4
A/E+: 314



141
4
A/E+: 330



142
2
A/E+: 316



143
2
A/E+: 300



144
4
A/E+: 352



145
2
A/E+: 316



146
2
A/E+: 338



147
4
ESI+: 307



148
4
A/E+: 346



149
4
A/E+: 314



150
36
A/E−: 308



151
36
A/E−: 358



152
11
ESI+: 369



153
35
ND



154
2
A/E+: 293



155
4
ESI+: 352



156
2
FAB+: 332



157
35
A/E+: 258



158
32
A/E+: 222



159
4
A/E+: 330



160
4
A/E+: 330



161
4
A/E+: 296



162
4
A/E+: 296



163
4
A/E+: 346



164
32
A/E+: 272



165
2
ESI+: 337



166
2
ESI+: 316



167
2
ESI+: 316



168
2
ESI+: 282



169
2
ESI+: 282



170
2
A/E+: 332



171
11
ESI+: 354



172
11
FAB+: 404



173
4
A/E+: 346, 348



174
4
A/E+: 336



175
9
A/E+: 301



176
4
ND



177
2
A/E+: 332, 334



178
2
A/E+: 322



179
2
A/E+: 372



180
2
ESI+: 287



181
4
A/E+: 346, 348



182
2
A/E+: 332



183
4
A/E+: 330



184
4
A/E+: 316, 318



185
2
A/E+: 316



186
4
A/E+: 344



187
4
ESI+: 330



188
2
ESI+: 302



189
2
ESI+: 330



190
2
ESI+: 316



191
2
A/E+: 304



192
4
A/E+: 330



193
4
A/E+: 316



194
2
ND



195
4
ND



196
2
A/E+: 302



197
2
A/E+: 254



198
4
A/E+: 330



199
2
A/E+: 316



200
11
ESI+: 415, 417



201
4
A/E+: 396, 398



202
4
A/E+: 348



203
4
A/E+: 282



204
2
A/E+: 327



205
2
A/E+: 334



206
2
A/E+: 268



207
4
A/E+: 330



208
4
ND



209
2
A/E−: 314



210
5
A/E+: 316



211
2
A/E+: 296



212
4
A/E+: 342



213
2
A/E+: 302



214
4
A/E+: 242



215
2
A/E+: 328



216
2
A/E+: 228



217
2
A/E+: 320



218
5
A/E+: 316



219
5
A/E+: 298



220
2
A/E+: 302



221
2
A/E+: 284



222
4
A/E+: 336





















TABLE 43







PEx
Syn
Dat




















223
4
A/E+: 318



224
4
A/E+: 268



225
2
ESI+: 322



226
2
ESI+: 304



227
5
A/E+: 262



228
2
A/E+: 248



229
4
A/E+: 342



230
2
A/E+: 254



231
2
A/E+: 321



232
2
ESI+: 328



233
19
A/E+: 329



234
4
A/E+: 334



235
4
ESI+: 334



236
4
A/E+: 334



237
4
A/E+: 318



238
4
A/E+: 307



239
4
A/E+: 344



240
4
A/E+: 328



241
2
ESI+: 320



242
2
ESI+: 320



243
2
ESI+: 304



244
2
ESI+: 293



245
4
A/E+: 328



246
4
A/E+: 310



247
2
A/E+: 300



248
2
ESI+: 330



249
11
ESI+: 364



250
2
A/E+: 282



251
2
A/E+: 300



252
4
A/E+: 346



253
4
A/E+: 328



254
4
A/E+: 328



255
2
ESI+: 332



256
2
A/E+: 314



257
27
A/E+: 334, 336



258
2
A/E+: 314



259
22
A/E+: 266



260
4
A/E+: 368



261
11
ESI+: 378



262
2
A/E+: 354



263
4
A/E+: 360



264
2
A/E+: 332



265
2
ESI+: 320



266
6
A/E+: 358



267
2
A/E+: 344



268
5
A/E+: 362, 364



269
2
ESI+: 334



270
5
A/E+: 344



271
2
A/E+: 316



272
4
ND



273
5
A/E+: 302, 304



274
11
A/E+: 404



275
37
A/E+: 246



276
4
ESI+: 386



277
4
ESI+: 368



278
2
A/E+: 288



279
22
A/E+: 252



280
4
A/E+: 344



281
24
A/E+: 264, 266



282
2
ESI+: 372



283
2
ESI+: 354



284
5
A/E+: 362, 364



285
5
A/E+: 342



286
2
A/E+: 330



287
2
A/E+: 330



288
24
A/E+: 270, 272



289
5
A/E+: 328



290
5
A/E+: 332, 334



291
5
A/E+: 323, 325



292
5
A/E+: 353, 355



293
2
A/E+: 314, 316



294
2
A/E+: 318, 320



295
5
A/E+: 348, 350



296
5
A/E+: 330, 332



297
5
A/E+: 324



298
5
A/E+: 276



299
2
A/E+: 339, 341



300
2
A/E−: 346, 348



301
2
A/E+: 334, 336



302
2
A/E+: 309



303
2
A/E+: 316, 318



304
2
A/E+: 207



305
2
A/E+: 296



306
5
A/E+: 317, 319



307
5
A/E+: 329, 331



308
2
A/E+: 262, 264



309
2
A/E+: 303, 305



310
2
A/E+: 315, 317



311
5
A/E+: 288, 290



312
2
A/E+: 274



313
11
A/E+: 350



314
4
A/E+: 332



315
11
A/E+: 368



316
4
A/E+: 350



317
2
ESI+: 318



318
2
ESI+: 336



319
2
A/E+: 314



320
4
A/E+: 314



321
5
A/E+: 330, 332



322
5
A/E+: 330, 332



323
2
ESI+: 300



324
2
A/E+: 316, 318



325
2
A/E+: 316, 318



326
5
A/E+: 362, 364



327
5
A/E+: 346, 348



328
2
A/E+: 348, 350



329
2
ND



330
5
A/E+: 341



331
2
A/E+: 327, 329



332
5
A/E+: 344, 346



333
11
FAB+: 378





















TABLE 44







PEx
Syn
Dat




















334
4
A/E+: 360



335
2
A/E+: 316, 318



336
2
A/E+: 332



337
38
A/E+: 204



338
11
A/E+: 336



339
4
A/E+: 300



340
2
A/E+: 277, 279



341
4
A/E+: 342



342
2
ESI+: 286



343
2
A/E+: 314



344
4
A/E+: 358



345
4
ESI+: 324



346
4
A/E+: 361



347
4
A/E+: 372



348
2
ESI+: 296



349
37
A/E+: 250



350
2
A/E+: 333



351
2
A/E+: 344



352
4
A/E+: 340



353
4
ESI+: 380



354
9
A/E+: 319



355
11
A/E+: 354



356
6
ESI+: 340



357
2
ESI+: 326



358
6
ESI+: 340



359
2
ESI+: 305



360
2
A/E+: 330, 332



361
2
A/E−: 310, 312



362
4
A/E+: 358



363
4
A/E+: 341, 343



364
4
ESI+: 330



365
4
ESI+: 300



366
4
ESI+: 316



367
2
ESI+: 316



368
2
ESI+: 286



369
2
ESI+: 302



370
11
ESI+: 382



371
2
ESI+: 328



372
4
A/E+: 346



373
2
A/E+: 330



374
4
A/E+: 363, 364



375
2
A/E+: 313



376
2
A/E+: 318



377
4
A/E+: 317



378
4
A/E+: 362



379
2
ND



380
30
A/E−: 270



381
4
A/E+: 354



382
2
A/E+: 334, 336



383
4
A/E+: 328



384
2
ESI+: 303



385
2
A/E+: 300



386
4
A/E+: 346



387
2
A/E+: 326



388
2
A/E+: 320



389
2
A/E+: 332, 334



390
4
A/E+: 350, 352



391
4
A/E+: 332, 334



392
2
A/E+: 318



393
2
A/E+: 336, 338



394
9
A/E+: 335



395
4
ESI+: 301



396
2
ESI+: 321



397
2
ESI+: 287



398
4
A/E+: 317



399
4
A/E+: 333, 335



400
9
A/E+: 335



401
11
ESI+: 404



402
2
ESI+: 321



403
2
A/E+: 319, 321



404
4
A/E+: 316, 318



405
4
A/E+: 346



406
4
A/E+: 353, 355



407
2
A/E+: 303



408
2
A/E+: 332, 334



409
4
A/E+: 362, 364



410
17
A/E+: 328



411
6
ESI+: 314



412
2
A/E+: 302, 304



413
2
A/E+: 300



414
2
A/E+: 339, 341



415
4
ESI+: 350



416
2
ESI+: 314



417
2
A/E+: 348, 350



418
9
A/E+: 351



419
2
ESI+: 336



420
4
A/E+: 350, 352



421
2
ESI+: 337



422
4
ESI+: 300



423
4
ESI+: 350



424
4
ESI+: 350



425
4
ESI+: 350



426
2
ESI+: 286



427
2
ESI+: 336



428
2
ESI+: 336



429
2
ESI+: 336



430
4
A/E+: 362, 364



431
4
A/E+: 366, 368



432
4
A/E+: 334, 336



433
4
A/E+: 330, 332



434
5
A/E+: 360, 362



435
2
A/E+: 316, 318



436
4
ESI+: 282



437
4
ESI+: 296



438
4
ESI+: 300



439
4
ESI+: 316



440
5
A/E+: 379, 380



441
4
A/E+: 262, 264



442
4
A/E+: 298, 300



443
6
ESI+: 326



444
2
A/E+: 348, 350





















TABLE 45







PEx
Syn
Dat




















445
4
A/E+: 368



446
2
ESI+: 268



447
2
ESI+: 282



448
2
ESI+: 286



449
2
ESI+: 302



450
4
A/E+: 350, 352



451
16
ESI+: 328



452
4
ESI+: 332



453
2
A/E+: 284, 286



454
2
ESI+: 336



455
2
A/E+: 336, 338



456
2
ESI+: 318



457
2
A/E+: 354



458
2
A/E+: 332, 334



459
4
ESI+: 360, 362



460
4
ESI+: 376, 378, 380



461
4
ESI+: 334



462
2
A/E+: 248, 250



463
4
ESI+: 334



464
6
A/E+: 312, 314



465
2
ESI+: 352, 354, 356



466
2
ESI+: 320, 322



467
4
ESI+: 366, 368, 370



468
4
ESI+: 334, 336



469
2
A/E+: 351, 353



470
2
A/E+: 320, 322



471
2
ESI+: 320



472
2
ESI+: 320



473
2
A/E+: 350, 352



474
2
ESI+: 282



475
2
A/E+: 315



476
2
ND



477
15
ESI+: 330



478
2
A/E+: 316



479
4
ESI+: 394, 396, 398



480
6
ESI+: 330, 332



481
4
A/E+: 352, 354



482
4
A/E+: 334, 336



483
14
A/E+: 371



484
4
ESI+: 361, 363



485
6
A/E+: 315



486
2
ESI+: 338, 340



487
2
A/E+: 320, 322



488
4
ESI+: 350, 352



489
4
ESI+: 330



490
4
ESI+: 346



491
4
ESI+: 346



492
4
ESI+: 318



493
2
ESI+: 336, 338



494
2
ESI+: 316, 318



495
4
ESI+: 312, 314



496
4
ESI+: 330



497
2
ND



498
2
ESI+: 316



499
2
ESI+: 332



500
2
ESI+: 332



501
2
ESI+: 304



502
6
ESI+: 297



503
4
ESI+: 326



504
2
ESI+: 298



505
2
ESI+: 283



506
2
ESI+: 316, 318



507
2
ESI+: 312, 315



508
12
ESI+: 302



509
12
ESI+: 318



510
6
ESI+: 308



511
9
ESI+: 379, 381



512
17
ESI+: 310



513
16
ESI+: 310



514
21
ESI+: 332



515
6
ESI+: 327



516
2
ESI+: 318



517
16
ESI+: 329



518
21
ESI+: 351



519
2
ESI+: 337



520
2
ESI+: 296


















TABLE 46





PEx
Dat (NMR)







128
DMSO-d6: 1.70 (6H, s), 7.94-7.96 (1H, m), 8.04-8.06 (2H, m),



8.84-8.87 (1H, m), 11.65-11.68 (1H, brs)


139
CDCl3: 4.04 (3H, s), 7.60 (1H, d, J = 6 Hz), 8.57 (1H, s),



8.74 (1H, s), 9.20 (1H, d, J = 6 Hz)


208
CDCl3: 1.54 (6H, s), 3.93 (3H, s), 7.23-7.35 (3H, m), 7.40



(1H, d, J = 4 Hz), 8.19 (1H, s), 8.23 (1H, s), 9.08 (1H, d,



J = 4 Hz)


272
CDCl3: 2.83 (3H, s), 2.88 (3H, s), 3.89 (3H, s), 7.18-7.27



(2H, m), 7.41-7.45 (2H, m), 7.98 (1H, s), 8.14 (1H, s)



















TABLE 47






Ex
Sal
Str



















1
2HCl


embedded image








2
Fum


embedded image








3
2HCl


embedded image








4
2HCl


embedded image








5
2HCl


embedded image








6
2HCl


embedded image








7
2HCl


embedded image








8
2HCl


embedded image








9
2HCl


embedded image








10
2HCl


embedded image








11
2HCl


embedded image








12
2HCl


embedded image








13
2HCl


embedded image





















TABLE 48






Ex
Sal
Str








14
2HCl


embedded image








15
2HCl


embedded image








16
2HCl


embedded image








17
2HCl


embedded image








18
2HCl


embedded image








19
2HCl


embedded image








20
2HCl


embedded image








21
2HCl


embedded image








22
2HCl


embedded image








23
2HCl


embedded image








24
2HCl


embedded image








25
HCl


embedded image








26
2HCl


embedded image








27
HCl


embedded image




















TABLE 49





Ex
Sal
Str







28
HCl


embedded image







29
HCl


embedded image







30
HCl


embedded image







31
HCl


embedded image







32
2HCl


embedded image







33
2HCl


embedded image







34
HCl


embedded image







35
2HCl


embedded image







36
2HCl


embedded image







37
2HCl


embedded image







38
2HCl


embedded image







39
2HCl


embedded image




















TABLE 50





Ex
Sal
Str







40
2HCl


embedded image







41
2HCl


embedded image







42
2HCl


embedded image







43
2HCl


embedded image







44
2HCl


embedded image







45
2HCl


embedded image







46
2HCl


embedded image







47
2HCl


embedded image







48
2HCl


embedded image







49
2HCl


embedded image







50
2HCl


embedded image







51
2HCl


embedded image




















TABLE 51





Ex
Sal
Str







52
3HCl


embedded image







53
HCl


embedded image







54
2HCl


embedded image







55
2HCl


embedded image







56
2HCl


embedded image







57
2HCl


embedded image







58
2HCl


embedded image







59
2HCl


embedded image







60
2HCl


embedded image







61
2HCl


embedded image







62
2HCl


embedded image







63
2HCl


embedded image







64
2HCl


embedded image





















TABLE 52






Ex
Sal
Str








65
2HCl


embedded image








66
2HCl


embedded image








67
2HCl


embedded image








68
2HCl


embedded image








69
2HCl


embedded image








70
2HCl


embedded image








71
2HCl


embedded image








72



embedded image








73
2HCl


embedded image








74
2HCl


embedded image








75
2HCl


embedded image








76
2HCl


embedded image








77
2HCl


embedded image








78
2HCl


embedded image





















TABLE 53






Ex
Sal
Str








79
2HCl


embedded image








80
2HCl


embedded image








81
2HCl


embedded image








82
2HCl


embedded image








83
2HCl


embedded image








84
2HCl


embedded image








85
2HCl


embedded image








86
2HCl


embedded image








87
2HCl


embedded image








88
2HCl


embedded image








89
2HCl


embedded image








90
Fum


embedded image





















TABLE 54






Ex
Sal
Str



















91
HCl


embedded image








92
Fum


embedded image








93
2HCl


embedded image








94
2HCl


embedded image








95
2HCl


embedded image








96
2HCl


embedded image








97
2HCl


embedded image








98
2HCl


embedded image








99
2HCl


embedded image








100
2HCl


embedded image








101
2HCl


embedded image








102
2HCl


embedded image








103
2HCl


embedded image





















TABLE 55






Ex
Sal
Str








104
3HCl


embedded image








105
2HCl


embedded image








106
3HCl


embedded image








107
2HCl


embedded image








108
2HCl


embedded image








109
2HCl


embedded image








110
2HCl


embedded image








111
2HCl


embedded image








112
2HCl


embedded image








113
2HCl


embedded image








114
2HCl


embedded image








115
2HCl


embedded image




















TABLE 56





Ex
Sal
Str







116
2HCl


embedded image







117
2HCl


embedded image







118
2HCl


embedded image







119
2HCl


embedded image







120
2HCl


embedded image







121
2HCl


embedded image







122
2HCl


embedded image







123
2HCl


embedded image







124
2HCl


embedded image







125
2HCl


embedded image







126
2HCl


embedded image







127
3HCl


embedded image




















TABLE 57





Ex
Sal
Str







128
2HCl


embedded image







129
2HCl


embedded image







130
2HCl


embedded image







131
3HCl


embedded image







132
2HCl


embedded image







133
Fum


embedded image







134
2HCl


embedded image







135
Fum


embedded image







136
Fum


embedded image







137
Fum


embedded image







138
Fum


embedded image







139
Fum


embedded image







140
2Fum


embedded image




















TABLE 58





Ex
Sal
Str







141
Fum


embedded image







142
Fum


embedded image







143
Fum


embedded image







144
Fum


embedded image







145
Fum


embedded image







146
Fum


embedded image







147
Fum


embedded image







148
Fum


embedded image







149
Fum


embedded image







150
Fum


embedded image







151
Fum


embedded image







152
Fum


embedded image






















TABLE 59







Ex
Sal
Str









153
Fum


embedded image









154
Fum


embedded image









155
Fum


embedded image









156
Fum


embedded image









157
Fum


embedded image









158
Fum


embedded image









159
Fum


embedded image









160
Fum


embedded image









161
Fum


embedded image









162
Fum


embedded image









163
Fum


embedded image









164
Fum


embedded image























TABLE 60







Ex
Sal
Str









165
Fum


embedded image









166
Fum


embedded image









167
Fum


embedded image









168
Fum


embedded image









169
Fum


embedded image









170
Fum


embedded image









171
Fum


embedded image









172
Fum


embedded image









173
Fum


embedded image









174
Fum


embedded image









175
Fum


embedded image









176
Fum


embedded image























TABLE 61







Ex
Sal
Str









177
Fum


embedded image









178
Fum


embedded image









179
Fum


embedded image









180
Fum


embedded image









181
Fum


embedded image









182
Fum


embedded image









183
Fum


embedded image









184
Fum


embedded image









185
Fum


embedded image









186
Fum


embedded image









187
Fum


embedded image









188
Fum


embedded image























TABLE 62







Ex
Sal
Str









189
Fum


embedded image









190
Fum


embedded image









191
Fum


embedded image









192
Fum


embedded image









193
Fum


embedded image









194
Fum


embedded image









195
Fum


embedded image









196
Fum


embedded image









197
HCl


embedded image









198
Fum


embedded image









199
Fum


embedded image









200
Fum


embedded image























TABLE 63







Ex
Sal
Str









201
Fum


embedded image









202
Fum


embedded image









203
Fum


embedded image









204
Fum


embedded image









205
Fum


embedded image









206
Fum


embedded image









207
Fum


embedded image









208
Fum


embedded image









209
2HCl


embedded image









210
Fum


embedded image









211
Fum


embedded image









212
Fum


embedded image























TABLE 64







Ex
Sal
Str









213
Fum


embedded image









214
Fum


embedded image









215
Fum


embedded image









216
Fum


embedded image









217
Fum


embedded image









218
Fum


embedded image









219
Fum


embedded image









220
Fum


embedded image









221
Fum


embedded image









222
Fum


embedded image









223
Fum


embedded image









224
Fum


embedded image





















TABLE 65





Ex
Sal
Str







225
HCl


embedded image







226
HCl


embedded image







227
2HCl


embedded image







228
Fum


embedded image



















TABLE 66





Ex
Dat
















1
ESI+: 345


2
ESI+: 375


3
ESI+: 359


4
ESI+: 291


5
ESI+: 345


6
ESI+: 359


7
ESI+: 357


8
ESI+: 361


9
ESI+: 359


10
ESI+: 359


11
ESI+: 343


12
ESI+: 316


13
ESI+: 361


14
ESI+: 343


15
ESI+: 343


16
ESI+: 305


17
ESI+: 359


18
ESI+: 359


19
ESI+: 359


20
ESI+: 361


21
ESI+: 343


22
ESI+: 343


23
ESI+: 375


24
ESI+: 373


25
ESI+: 377


26
ESI+: 427


27
ESI+: 393


28
ESI+: 377


29
ESI+: 361


30
ESI+: 388


31
ESI+: 341


32
ESI+: 341


33
ESI+: 316


34
ESI+: 377


35
ESI+: 321


36
ESI+: 346


37
ESI+: 377


38
ESI+: 377


39
ESI+: 359


40
ESI+: 357


41
ESI+: 357


42
ESI+: 341


43
ESI+: 379


44
ESI+: 341


45
ESI+: 373, 375


46
ESI+: 373


47
ESI+: 373


48
ESI+: 357


49
ESI+: 357


50
ESI+: 323


51
ESI+: 323


52
ESI+: 328


53
ESI+: 413


54
ESI+: 363


55
ESI+: 373


56
ESI+: 357


57
ESI+: 343


58
ESI+: 371


59
ESI+: 357


60
ESI+: 361


61
ESI+: 357


62
ESI+: 295


63
ESI+: 343


64
ESI+: 357


65
ESI+: 375


66
ESI+: 309


67
ESI+: 357


68
ESI+: 337


69
ESI+: 343


70
ESI+: 369


71
ESI+: 269


72
ESI+: 370


73
ESI+: 343, 345


74
ESI+: 325, 327


75
ESI+: 295


76
ESI+: 289


77
ESI+: 369, 371


78
ESI+: 371


79
ESI+: 341


80
A/E+: 341


81
ESI+: 385


82
A/E+: 323


83
ESI+: 373


84
ESI+: 355


85
ESI+: 355


86
ESI+: 395


87
ESI+: 373


88
ESI+: 375, 377


89
ESI+: 357


90
ESI+: 413


91
ESI+: 371, 373


92
ESI+: 395


93
ESI+: 355, 357


94
A/E+: 371


95
ESI+: 359, 361


96
A/E+: 389, 391


97
ESI+: 380, 382


98
ESI+: 350, 352


99
ESI+: 375, 377


100
ESI+: 393, 395


101
ESI+: 357, 359


102
ESI+: 329, 331


103
ESI+: 303, 305


104
ESI+: 344, 346


105
ESI+: 337


106
ESI+: 356, 358


107
ESI+: 315, 317


108
ESI+: 355


109
ESI+: 357, 359


110
ESI+: 357, 359


111
ESI+: 389, 391

















TABLE 67





Ex
Dat







112
ESI+: 373, 375


113
ESI+: 368


114
ESI+: 373


115
ESI+: 357


116
ESI+: 318


117
ESI+: 355


118
ESI+: 337


119
ESI+: 385


120
ESI+: 374


121
ESI+: 371, 373


122
ESI+: 353, 355


123
ESI+: 359


124
ESI+: 375, 377


125
ESI+: 341


126
ESI+: 371, 373


127
ESI+: 354, 356


128
ESI+: 375, 377


129
ESI+: 367


130
ESI+: 373, 375


131
ESI+: 356


132
ESI+: 391, 393


133
FAB+: 291


134
ESI+: 343


135
ESI+: 359


136
ESI+: 343


137
ESI+: 359


138
ESI+: 359


139
ESI+: 316


140
ESI+: 350


141
ESI+: 334


142
ESI+: 379


143
ESI+: 370


144
ESI+: 363


145
ESI+: 345


146
ESI+: 361


147
ESI+: 361


148
ESI+: 345


149
ESI+: 362


150
ESI+: 334


151
ESI+: 361


152
ESI+: 359


153
A/E+: 359


154
ESI+: 377


155
ESI+: 341


156
ESI+: 367


157
ESI+: 346


158
ESI+: 369


159
ESI+: 357


160
ESI+: 327


161
ESI+: 343


162
ESI+: 361


163
ESI+: 344


164
ESI+: 362


165
ESI+: 328


166
ESI+: 373


167
ESI+: 359, 361


168
ESI+: 377, 379


169
ESI+: 360, 362


170
ESI+: 341


171
ESI+: 362


172
ESI+: 355


173
ESI+: 344, 346


174
ESI+: 373, 375


175
ESI+: 343, 345


176
ESI+: 377, 379


177
ESI+: 389, 391


178
ESI+: 378


179
ESI+: 327


180
ESI+: 377


181
ESI+: 377


182
ESI+: 377


183
ESI+: 377, 379


184
ESI+: 380, 382


185
ESI+: 357, 359


186
ESI+: 389, 391


187
ESI+: 377


188
ESI+: 309


189
ESI+: 323


190
ESI+: 327


191
ESI+: 343


192
ESI+: 323


193
ESI+: 339, 341


194
ESI+: 325


195
ESI+: 377, 379


196
ESI+: 395


197
ESI+: 357


198
ESI+: 289, 291


199
ESI+: 359


200
ESI+: 361


201
ESI+: 361


202
ESI+: 357


203
ESI+: 373


204
ESI+: 373


205
ESI+: 345


206
ESI+: 357, 359


207
ESI+: 342


208
ESI+: 324


209
ESI+: 361, 363


210
ESI+: 393, 395


211
ESI+: 361, 363


212
ESI+: 379, 381


213
ESI+: 339, 341


214
ESI+: 361, 363


215
ESI+: 359


216
ESI+: 343


217
ESI+: 343


218
ESI+: 359


219
ESI+: 337


220
ESI+: 357, 359


221
ESI+: 377, 379


222
ESI+: 353

















TABLE 68





Ex
Dat







223
ESI+: 378


224
ESI+: 357


225
ESI+: 291


226
ESI+: 345


227
ESI+: 345


228
ESI+: 327

















TABLE 69





Ex
Dat (NMR-DMSO-d6)
















2
5.03 (2H, s), 5.51 (1H, brs), 6.62 (2H, s), 7.45-7.51 (2H, m), 8.25 (1H, d, J = 8.8



Hz), 8.32 (1H, s), 8.51 (1H, dd, J = 8.8, 1.6 Hz), 8.66 (1H, s)


6
2.80 (3H, s), 7.44-7.52 (2H, m), 7.73 (1H, s), 8.24 (1H, d, J = 8.9 Hz), 8.37 (1H,



brs), 8.47 (1H, dd, J = 8.8, 2.0 Hz), 8.54 (2H, brs), 8.74 (2H, brs)


17
1.99 (3H, s), 7.50 (2H, t, J = 7.8 Hz), 8.23 (1H, s), 8.28 (1H, d, J = 8.8 Hz),



8.42-8.46 (1H, m), 8.57 (2H, brs), 8.78 (2H, brs), 9.15 (1H, s)


31
2.28 (3H, s), 7.31-7.40 (1H, m), 7.50-7.59 (2H, m), 8.09 (1H, s), 8.24 (1H, d, J =



8.8 Hz), 8.41-8.47 (1H, m), 8.55 (2H, brs), 8.70 (2H, brs), 9.09 (1H, s)


60
7.36-7.40 (1H, m), 7.56-7.67 (2H, m), 8.15 (1H, s), 8.33 (1H, d, J = 8 Hz), 8.51



(1H, d, J = 8 Hz), 8.56 (2H, brs), 8.68 (2H, brs), 9.23 (1H, s), 12.33 (1H, brs)


73
7.45-7.50 (2H, m), 7.55-7.58 (2H, m), 8.12 (1H, s), 8.30 (1H, d, J = 8 Hz), 8.51



(1H, d, J = 8 Hz), 8.56 (2H, brs), 8.66 (2H, brs), 9.19 (1H, s), 12.22 (1H, brs)


74
7.47-7.49 (2H, m), 7.60-7.64 (2H, m), 8.12 (1H, s), 8.30 (1H, d, J = 8 Hz), 8.55



(2H, d, J = 8 Hz), 8.58 (2H, brs), 8.67 (2H, brs), 9.18 (1H, s), 12.23 (1H, brs)


95
7.51-7.54 (1H, m), 7.59-7.69 (3H, m), 7.75-7.77 (1H, m), 7.94 (1H, s), 8.31-8.34



(1H, m), 8.58-8.60 (3H, m), 8.69 (2H, brs), 9.24 (1H, s)


108
2.23 (3H, s), 2.87 (3H, s), 7.35-7.40 (1H, m), 7.48-7.60 (2H, m), 8.05 (1H, s),



8.30 (1H, d, J = 8 Hz), 8.52 (1H, d, J = 8 Hz), 8.58 (2H, brs), 8.73 (2H, brs),



12.34 (1H, brs)


109
1.96 (3H, s), 7.26-7.39 (3H, m), 7.95 (1H, s), 8.31 (1H, d, J = 10 Hz), 8.59 (1H,



d, J = 10 Hz), 8.64 (2H, brs), 8.78 (2H, brs), 9.20 (1H, s)


114
2.26 (3H, s), 2.87 (3H, s), 7.50-7.54 (2H, m), 8.20 (1H, s), 8.29 (1H, d, J = 9.0



Hz), 8.51 (1H, d, J = 9.0 Hz), 8.62 (2H, brs), 8.83 (2H, brs), 9.12 (1H, s)


115
2.86 (3H, s), 7.44-7.53 (4H, m), 7.99 (1H, s), 8.21 (1H, d, J = 8 Hz), 8.41 (1H, d,



J = 8 Hz), 8.53 (4H, brs), 11.98 (1H, brs)


117
2.25 (3H, s), 2.85 (3H, s), 7.40-7.44 (2H, m), 7.74-7.78 (1H, m), 8.02 (1H, s),



8.26 (1H, d, J = 10 Hz), 8.54 (1H, d, J = 10 Hz), 8.61 (2H, brs), 8.74 (2H, brs),



9.12 (1H, s)


126
2.17 (3H, s), 2.86 (3H, s), 7.48-7.51 (2H, m), 7.78 (1H, dd, J = 8.2, 2.1 Hz), 7.90



(1H, d, J = 1.8 Hz), 8.28 (1H, d, J = 8.8 Hz), 8.51 (1H, d, J = 8.9 Hz), 8.56 (2H,



brs), 8.72 (2H, brs)


141
6.62 (2H, s), 7.82-7.86 (1H, m), 7.94 (1H, d, J = 7.9 Hz), 8.00 (1H, d, J = 5.6



Hz), 8.09 (1H, d, J = 8.6 Hz), 8.13 (1H, d, J = 9.6 Hz), 8.36 (1H, s), 8.49 (1H, d,



J = 8.6 Hz), 8.67 (1H, d, J = 5.7 Hz)


144
6.63 (2H, s), 7.50 (2H, t, J = 8.2 Hz), 8.24 (1H, d, J = 8.7 Hz), 8.35 (1H, s), 8.63



(1H, d, J = 8.7 Hz), 8.72 (1H, s)

















TABLE 70





Ex
Dat (NMR-DMSO-d6)







147
6.63 (2H, s), 7.51 (1H, t, J = 8.4 Hz), 7.61 (1H, d, J = 8.0 Hz), 7.65-7.74 (1H, m),



8.19 (1H, s), 8.24 (1H, d, J = 8.7 Hz), 8.60-8.66 (1H, m), 8.71 (1H, s)


148
6.63 (2H, s), 7.38 (2H, t, J = 8.0 Hz), 7.67-7.80 (1H, m), 8.24 (1H, d, J = 8.7 Hz),



8.32 (1H, brs), 8.60-8.64 (1H, m), 8.71 (1H, d, J = 1.7 Hz)


149
6.63 (2H, s), 8.34 (1H, s), 8.35 (1H, d, J = 8.9 Hz), 8.69 (1H, d, J = 8.9 Hz), 8.87



(2H, s), 8.91 (1H, s)


151
6.63 (2H, s), 7.42-7.49 (1H, m), 7.59-7.65 (1H, m), 7.68-7.73 (1H, m), 8.21 (1H,



d, J = 8.7 Hz), 8.24 (1H, s), 8.59 (1H, d, J = 8.7 Hz), 8.64 (1H, s)


152
2.69 (3H, s), 6.63 (2H, s), 7.45-7.49 (2H, m), 8.16 (1H, d, J = 8.8 Hz), 8.30 (1H,



s), 8.53 (1H, d, J = 8.8 Hz), 8.54 (1H, s)


156
0.89-0.94 (2H, m), 1.12-1.17 (2H, m), 2.42-2.48 (1H, m), 6.62 (2H, s), 7.32-7.38



(2H, m), 7.66-7.73 (1H, m), 8.28 (1H, s), 8.43 (1H, s), 8.47 (1H, d, J = 8.8 Hz),



8.53-8.56 (1H, m)


157
6.63 (2H, s), 8.29 (1H, d, J = 8.7 Hz), 8.33 (1H, brs), 8.62-8.67 (1H, m), 8.79



(1H, d, J = 1.8 Hz), 8.87 (2H, s)


158
1.46 (6H, d, J = 7.2 Hz), 3.75-3.85 (1H, m), 6.62 (2H, s), 7.32-7.38 (2H, m),



7.66-7.73 (1H, m), 8.28-8.31 (2H, m), 8.50-8.53 (1H, m), 8.62 (1H, s)


159
3.67 (3H, s), 6.63 (2H, s), 7.03 (1H, t, J = 8.5 Hz), 7.11 (1H, d, J = 8.5 Hz),



7.56-7.64 (1H, m), 8.18 (1H, d, J = 8.7 Hz), 8.23 (1H, s), 8.57-8.61 (1H, m), 8.63 (1H,



d, J = 1.9 Hz)


160
6.63 (2H, s), 7.41-7.50 (2H, m), 7.56-7.70 (2H, m), 8.21 (1H, d, J = 8.7 Hz), 8.42



(1H, brs), 8.58-8.64 (1H, m), 8.66 (1H, d, J = 1.9 Hz)


161
6.63 (2H, s), 7.51-7.65 (3H, m), 7.68-7.72 (1H, m), 8.20 (1H, d, J = 8.8 Hz), 8.23



(1H, s), 8.57-8.62 (1H, m), 8.64 (1H, d, J = 1.9 Hz)


162
6.63 (2H, s), 7.38-7.42 (2H, m), 7.72-7.74 (1H, m), 8.30-8.34 (2H, m), 8.66-8.67



(1H, m), 8.88 (1H, s)


164
6.63 (2H, s), 8.20 (1H, s), 8.28 (1H, d, J = 8.7 Hz), 8.62-8.67 (1H, m), 8.78 (1H,



d, J = 1.8 Hz), 8.89 (1H, s), 8.92 (1H, s)


169
6.63 (2H, s), 7.69 (1H, d, J = 5.2 Hz), 8.22 (1H, s), 8.31 (1H, d, J = 8.8 Hz), 8.66



(1H, d, J = 8.8 Hz), 8.78 (1H, d, J = 5.2 Hz), 8.84 (1H, s), 8.92 (1H, s)


170
2.69 (3H, s), 6.62 (2H, s), 7.32-7.39 (2H, m), 7.66-7.73 (1H, m), 8.15 (1H, d, J =



8.8 Hz), 8.28 (1H, brs), 8.41-8.54 (2H, m)


171
6.62 (2H, s), 8.20 (1H, s), 8.28 (1H, d, J = 8.7 Hz), 8.62-8.67 (1H, m), 8.78 (1H,



d, J = 1.8 Hz), 8.89 (1H, s), 8.92 (1H, s)

















TABLE 71





Ex
Dat (NMR-DMSO-d6)







172
1.39 (3H, t, J = 7.6 Hz), 3.15 (2H, q, J = 7.6 Hz), 6.63 (2H, s), 7.32-7.39 (2H, m),



7.66-7.74 (1H, m), 8.22 (1H, d, J = 8.8 Hz), 8.29 (1H, s), 8.50-8.56 (2H, m)


174
3.68 (3H, s), 6.63 (2H, s), 6.96-7.01 (1H, m), 7.16-7.19 (1H, m), 7.40-7.44 (1H,



m), 8.21 (1H, d, J = 8 Hz), 8.35 (1H, brs), 8.59 (1H, d, J = 8 Hz), 8.72 (1H, s)


176
6.62 (2H, s), 7.44-7.49 (1H, m), 7.63-7.67 (1H, m), 7.71-7.74 (1H, m), 8.25-8.28



(2H, m), 8.63-8.65 (1H, m), 8.78 (1H, s)


187
6.63 (2H, s), 7.38-7.44 (2H, m), 7.70 (1H, t, J = 54 Hz), 7.72-7.79 (1H, m), 8.32



(1H, d, J = 8.8 Hz), 8.39 (1H, s), 8.62-8.65 (1H, m), 8.92 (1H, s)


192
2.67 (3H, s), 6.62 (2H, s), 7.40-7.45 (2H, m), 7.54-7.66 (2H, m), 8.12 (1H, d, J =



8.8 Hz), 8.40 (1H, brs), 8.49-8.52 (2H, m)


193
2.67 (3H, s), 6.62 (2H, s), 7.48-7.61 (3H, m), 7.65-7.68 (1H, m), 8.11 (1H, d, J =



8.8 Hz), 8.21 (1H, d, J = 1.5 Hz), 8.47-8.52 (2H, m)


206
2.69 (3H, s), 6.62 (2H, s), 7.45-7.50 (1H, m), 7.58 (1H, d, J = 8.0 Hz), 7.64-7.70



(1H, m), 8.13-8.16 (2H, m), 8.51-8.54 (2H, m)


207
2.72 (3H, s), 6.62 (2H, s), 8.20 (1H, d, J = 8.8 Hz), 8.27 (1H, brs), 8.54-8.56 (1H,



m), 8.59 (1H, brs), 8.84 (2H, s)


208
2.70 (3H, s), 6.62 (2H, s), 7.67-7.70 (1H, m), 8.17 (1H, d, J = 8.8 Hz), 8.38 (1H,



brs), 8.51-8.56 (2H, m), 8.66-8.68 (1H, m), 8.83 (1H, brs)


215
6.62 (2H, s), 7.44-7.81 (5H, m), 8.29 (1H, d, J = 8.7 Hz), 8.49 (1H, brs), 8.59-



8.62 (1H,m), 8.87 (1H, s)


219
1.37 (3H, t, J = 7.5 Hz), 3.13 (2H, q, J = 7.5 Hz), 6.62 (2H, s), 7.40-7.45 (2H, m),



7.55-7.65 (2H, m), 8.18 (1H, d, J = 8.8 Hz), 8.40 (1H, brs), 8.48-8.52 (2H, m)


223
6.63 (2H, s), 7.73 (1H, t, J = 54 Hz), 8.35-8.39 (2H, m), 8.66 (1H, dd, J = 8.8, 1.6



Hz), 8.89 (2H, s), 8.97 (1H, s)


224
5.03 (2H, s), 5.49 (1H, brs), 6.62 (2H, s), 7.33-7.39 (2H, m), 7.67-7.74 (1H, m),



8.24 (1H, d, J = 8.8 Hz), 8.29 (1H, brs), 8.50-8.53 (1H, m), 8.65 (1H, s)



















TABLE 72







PEx
Str









521


embedded image









522


embedded image









523


embedded image









524


embedded image









525


embedded image









526


embedded image









527


embedded image









528


embedded image









529


embedded image









530


embedded image






















TABLE 73







PEx
Str









531


embedded image









532


embedded image









533


embedded image









534


embedded image









535


embedded image









536


embedded image









537


embedded image









538


embedded image









539


embedded image









540


embedded image






















TABLE 74







PEx
Str









541


embedded image









542


embedded image









543


embedded image









544


embedded image









545


embedded image









546


embedded image









547


embedded image









548


embedded image









549


embedded image









550


embedded image






















TABLE 75







PEx
Str









551


embedded image









552


embedded image









553


embedded image









554


embedded image









555


embedded image









556


embedded image









557


embedded image









558


embedded image









559


embedded image









560


embedded image






















TABLE 76







PEx
Str









561


embedded image









562


embedded image









563


embedded image









564


embedded image









565


embedded image





















TABLE 77





PEx
Syn
Dat

















521
521
A/E+: 346


522
522
ESI+: 362, 364


523
523
ESI+: 319


524
2
ESI+: 336


525
4
ESI+: 348, 350


526
2
ESI+: 334, 336


527
4
ESI+: 332, 334


528
2
ESI+: 318, 320


529
4
ESI+: 346, 348


530
2
ESI+: 332, 334


531
2
ESI+: 302, 304


532
2
ESI+: 350, 352


533
4
ESI+: 364, 366


534
4
A/E+: 358, 360


535
4
ESI+: 330


536
4
ESI+: 346


537
2
ESI+: 348, 350


538
4
A/E+: 346, 348


539
12
ESI+: 318


540
12
ESI+: 302


541
2
ESI+: 316


542
2
ESI+: 332


543
4
ESI+: 364


544
6
ESI+: 356


545
2
NMR-DMSO-d6: 3.60 (1H, s), 6.88 (2H, d, J = 8 Hz),




7.53 (1H, t, J = 8 Hz), 8.16 (1H, brs), 8.31 (1H, d, J = 8




Hz), 8.37 (1H, d, J = 8 Hz), 8.82 (1H, s)


546
2
ESI+: 342


















TABLE 78





Ex
Syn
Dat

















547
17
ESI+: 329


548
2
ESI+: 315


549
2
A/E+: 350, 352


550
4
NMR-DMSO-d6: 2.37 (3H, brs), 3,89 (3H, s), 7.34 (1H,




t, J = 8 Hz), 7.42 (1H, t, J = 8 Hz), 7.56 (1H, t, J = 8




Hz), 8.36-8.46 (3H, m), 8.91 (1H, s)


551
2
A/E+: 332, 334


552
2
A/E+: 316


553
4
ESI+: 330


554
2
A/E+: 316


555
9
ESI+: 391


556
4
A/E+: 350, 352


557
2
ESI+: 305


558
4
ESI+: 316, 318


559
4
A/E+: 378, 380


560
2
A/E+: 382, 384


561
2
A/E+: 332


562
521
ESI+: 328


563
2
ESI+: 314


564
521
ESI+: 344, 346


565
2
A/E+: 330, 332




















TABLE 79







Ex
Sal
Str









229
Fum


embedded image









230
Fum


embedded image









231
Fum


embedded image









232
Fum


embedded image









233
Fum


embedded image









234
Fum


embedded image









235
Fum


embedded image









236
Fum


embedded image









237
Fum


embedded image









238
Fum


embedded image























TABLE 80







Ex
Sal
Str









239
Fum


embedded image









240
Fum


embedded image









241
Fum


embedded image









242
Fum


embedded image









243
Fum


embedded image









244
Fum


embedded image









245
Fum


embedded image









246
Fum


embedded image









247
Fum


embedded image









248
Fum


embedded image























TABLE 81







Ex
Sal
Str









249
Fum


embedded image









250
Fum


embedded image









251
Fum


embedded image




















TABLE 82





Ex
Dat







229
ESI+: 377, 379


230
ESI+: 375, 377


231
ESI+: 359, 361


232
ESI+: 373, 375


233
ESI+: 343, 345


234
ESI+: 391, 393


235
ESI+: 389, 391


236
ESI+: 359


237
ESI+: 357


238
ESI+: 373


239
ESI+: 343


240
ESI+: 383


241
ESI+: 356


242
ESI+: 385


243
ESI+: 373


244
ESI+: 391


245
ESI+: 357


246
ESI+: 357, 359


247
ESI+: 346


248
ESI+: 423, 425


249
ESI+: 373


250
ESI+: 355


251
ESI+: 371, 373









TEST EXAMPLES

Pharmacological activities of compound of formula (I) were confirmed by the following tests.


Test Example 1
Acquisition of HEK293 Cells for Forced Expressions of a Human 5-HT5A Receptor

The ORF (open reading frame; protein coding region) of a human 5-HT5A receptor (Genbank AF498985) was cloned from a human hippocampus cDNA library, and then inserted into a pCR2.1 vector (Invitrogen), and Escherichia coli containing the plasmid was cultured in a large amount. Next, the full-length cDNA sequence of the human 5-HT5A receptor was analyzed, and recombined into a pCDNA3.1 vector (Invitrogen) as an expression vector and cultured in a large amount. HEK293 established cells (ATCC) derived from the human fetal kidney were seeded, the expression plasmid (1 μg) obtained above were added thereto with LIPOFECTAMINE 2000 (Invitrogen; 2 μl), the gene was transfected into HEK293 cells, and the expression cells were screened with a drug-resistant marker, Geneticin (G418 sulfate 500 μg/ml; Kanto Chemical Co., Inc.). Thus prepared recombinant cells which expressed the gene were cultured in a medium containing D-MEM (Dulbecco's modified eagle medium, Sigma), 10% FCS (Fetal calf serum: fetal bovine serum), 1% Pc./Sm (Penicillin/Streptomycin, Invitrogen), and 500 μg/ml G418 for 3 days. These experimental operations followed a manual for gene operation experiment and an instruction appended in a reagent, and the like, such as a known method (Sambrook, J. et al, Molecular Cloning-A Laboratory Manual”, Cold Spring Harabor laboratory, NY, 1989).


Test Example 2
Test on a Human 5-HT5A Receptor Binding Inhibition

(1) Preparation of a Membrane from HEK293 Cells for Forced Expressions of a Human 5-HT5A Receptor


HEK293 cells for forced expressions of a human 5-HT5A receptor were cultured in a F500 plate, and scraped with a scraper. After centrifugation, the precipitate was collected, and an incubation buffer (50 mM Tris (HCl) (pH 7.4), 10 mM MgSO4, and 0.5 mM EDTA (ethylenediamine tetraacetic acid)) was added thereto. After homogenization, it was further centrifuged, and the incubation buffer was added to the precipitate, followed by thoroughly suspending. The operation was repeated, and protein concentration was measured, thereby completing preparation of the membrane.


(2) Test on a Human 5-HT5A Receptor Binding Inhibition


A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspended in an incubation buffer, and a membrane from HEK293 cells for forced expressions of a human 5-HT5A receptor prepared at 200 μg/ml was added at 100 μl/well. After incubation at room temperature for 15 minutes, a [3H]5-CT solution (2 nM [3H]5-CT, incubation buffer) was added thereto at 100 μl/well.


Separately, 100 μl of the solution was distributed into a liquid scintillation vial, and 2 ml of Aquasol II (registered trademark) was added thereto, followed by stirring. Then, radioactivity was measured by a liquid scintillation counter. It was incubated at 37° C. for 60 minutes. The reaction mixture was sucked into 96-well GF/C filter plate that had been pre-treated with 0.2% polyethyleneimine, and washed six times with an ice-cooled, 50 mM Tris (pH 7.5) buffer. The GF/C filter plate was dried.


Microscint TMPS (registered trademark) was added thereto at 40 μl/well. Radioactivity remaining on the GF/C filter plate was measured by a top counter.


The [3H]5-CT binding inhibiting activity by the compound to be tested in each experiment was determined as an IC50 value with a radioactivity upon addition of DMSO alone being 0% inhibition, and a radioactivity upon addition of 1 μM 5-CT being 100% inhibition. Separately, Ki values were calculated from the Kd value of the [3H]5-CT determined from Scatchard analysis, by the following equation.






Ki=IC
50(1+Concentraion of ligand added/Kd(4.95 nM))


As a result of this test, it was demonstrated that compound of formula (I) has a potent human 5-HT5A receptor binding inhibiting activity.


The compounds of Examples 1, 3, 5, 8 to 11, 13, 15 to 17, 19, 23, 24, 27, 31, 32, 39 to 42, 44, 46 to 51, 55 to 58, 61, 62, 65 to 67, 69, 70, 73, 74, 77, 83 to 85, 88, 89, 91, 93 to 99, 101, 102, 104, 107 to 117, 121, 123, 126, 130, 132, 134 to 138, 141, 142, 144 to 154, 157, 159 to 161, 164, 166 to 172, 175 to 190, 192 to 195, 197, 198, 200, 201, 203, 206 to 211, 213, 214, 216 to 222, and 226 showed Ki values ranging between 1 nM and 10 nM, respectively; the compounds of Examples 2, 4, 6, 7, 14, 18, 20 to 22, 25, 28 to 30, 33 to 36, 43, 45, 52, 54, 59, 63, 64, 68, 71, 75, 76, 78 to 82, 86, 87, 90, 100, 103, 105, 106, 118 to 120, 122, 124, 125, 127 to 129, 131, 133, 140, 143, 155, 156, 158, 163, 165, 173, 174, 191, 196, 199, 202, 204, 205, 212, 215, 224, 227, and 228 showed Ki values ranging between 10 nM and 100 nM, respectively; and the compounds of Examples 12, 37, 92, 139, and 225 showed Ki values ranging between 100 nM and 300 nM, respectively.


The Ki values of several compounds of Examples are shown in Tables below.












TABLE 83







Ex
Ki [nM]



















6
13



60
1.3



147
1.6



148
1.4



151
4.1



152
1.3



114
3.7



157
5.3



159
7.1



160
3.3



161
3.4



162
1.2



164
4.7



170
1.9



171
6.2



187
4.6



192
1.8



211
2.3










As described above, it was confirmed that compound of formula (I) has 5-HT5A receptor affinity.


Test Example 3
Evaluation of Various Drugs Towards the Drugs (Methamphetamine, MK-801) which Increase Quantity of Motion in Mice (Method for Measuring Quantity of Motion by IR Irradiation)

The improvement effect of compound of formula (I) on schizophrenia was evaluated by measuring the quantity of motion inhibited by administration of the compound in a model in which the symptoms were induced by methamphetamine (hereinafter abbreviated as MAP) and MK-801.


(1) Animal


Species: Male ICR mouse


(2) Operation Procedure


The animal was taken out of a breeding cage, orally administered with a test compound, and then placed into a cage for breeding. After 30 minutes, the animal was put into a cage for measurement, and the quantity of motion with the test compound alone was measured. Further, after 30 to 90 minutes, the animal was taken out, and subcutaneously or intraperitoneally administered with a drug for increasing the quantity of motion (MAP; 1.5 mg/kg or MK-801; 0.3 mg/kg, dissolved in physiological saline, respectively). Then, the quantity of motion for a certain period of time (60 minutes) was measured using a device for measuring the quantity of motion (CompACT AMS manufactured by Muromachi Kikai Co., Ltd.) by means of an infrared sensor.


(3) Analysis


For a normal mouse (a mouse administered with physiological saline) and a mouse administered with a drug for increasing the quantity of motion, a Student's T test was performed for evaluation for each interval. For a group administered with the test compound, an assay was performed using a solvent (vehicle) group and a Dunnett's T test. For the evaluation, if there was a significant difference (P<0.05), it was considered that there is an effect.


As a result of this test, compound of formula (I) inhibited the increase in the quantity of motion of the mouse. For example, the compounds of Examples 73, 148, 157, 160, 187, and 192 significantly inhibited the hyperactivity induced by MK-801 at doses of 0.1 mg/kg, 0.03 mg/kg, 0.03 mg/kg, 0.01 mg/kg, 0.01 mg/kg, and 0.01 mg/kg, respectively. Further, the compound of Example 148 significantly inhibited the hyperactivity induced by MAP at a dose of 0.1 mg/kg.


As described above, it was confirmed that compound of formula (I) has an improvement effect for the increase of the quantity of motion (hyperactivity) which is a symptom of schizophrenia.


Test Example 4
Improvement Effect on Spontaneous Alternation Behavior Induced by Scoporamine or MK-801 in Mice

The improvement effect of compound of formula (I) on cognitive impairment of dementia and schizophrenia was evaluated by a known test method as a model with short-term learning disorder.


(1) Animal


Species: Male ddY mouse


(2) Measurement Method


After 10 to 30 minutes from oral administration of the test compound, 0.5 mg/kg of Scoporamine or 0.15 mg/kg of MK-801 (in the case of a normal group, physiological saline was administered) was intraperitoneally administered. After 20 minutes, the test was conducted. In addition, solvent (vehicle) was orally administered to the normal group (to which physiological saline was administered) and to the control group (to which 0.5 mg/kg of Scoporamine or 0.15 mg/kg of MK-801 was administered), when the test compound was administered.


A mouse was placed at the end of one arm of a Y-maze having arms with the same length in three directions, and then allowed to explore freely and the number of arm entries was counted for 8 minutes. Further, spontaneous alternation behavior was defined as entries into all three different arms on consecutive occasions, and the ratio of the number of instances of this behavior to the total number of the entries was calculated as an alternation rate by the following formula:





Alternation rate(%)=Number of spontaneous alternation behaviors/(Total number of entries−2)×100.


(3) Data Analysis


If a significant difference between the normal group and the control group (Student's T test) was approved in the alternation rate (%), it was considered to have learning disorder by the administration of Scoporamine or MK-801. By carrying out a Dunnett's test on the group administered with the test compound with respect to the control group, the presence or absence of effect of the test compound on learning disorder was evaluated. For each assay, it was considered that there was a tendency when p<0.10 and there was a significant difference when p<0.05.


As a result of this test, compound of formula (I) inhibited the spontaneous alternation behavior in the mouse, induced by Scoporamine and MK-801. For example, the compound of Example 148 significantly inhibited spontaneous alternation behavior induced by Scoporamine at a dose of 0.01 mg/kg; the compound of Example 192 significantly inhibited spontaneous alternation behavior induced by Scoporamine at a dose of 0.003 mg/kg; the compounds of Examples 157 and 160 significantly inhibited spontaneous alternation behavior induced by Scoporamine at a dose of 0.001 mg/kg; and the compound of Example 187 significantly inhibited spontaneous alternation behavior induced by Scoporamine at a dose of 0.0003 mg/kg.


As a result of this test, it was confirmed that compound of formula (I) shows improvement effect on cognitive impairment of dementia and schizophrenia.


Test Example 5
Improvement Effect on Disorder of PCP-Induced Prepulse Inhibition (PPI) in Rats

When a sound stimulus is given to a human, a startled reaction occurs, but for a normal human, this startled reaction is inhibited when the sound stimulus is preceded by a weak sound stimulus. This inhibiting action is similarly lowered in a patient with schizophrenia. It is known that when a rat is administered with PCP (phencyclidine), a similar symptom to human schizophrenia occurs. Using this model, the improvement effect of compound of formula (I) on information processing disorder included in cognitive impairment of schizophrenia was evaluated.


The improvement effect of compound of formula (I) on schizophrenia was evaluated using a known model with PCP-induced prepulse inhibition disorder as a model with the condition of a disease. Specifically, it followed the method as described in “Neuropsychopharmacology, 1989; 2: 61-66, Mansbach, R. S. and Geyer, M. A. and Brain Research, 1998; 781: 227-235”.


As a result of this test, it was confirmed that compound of formula (I) also has an effect on information processing disorder included in cognitive impairment of schizophrenia.


Test Example 6
Evaluation of Drug on Water Maze Learning Disorder in Old Rats

The improvement effect of compound of formula (I) on dementia was evaluated using a known model with water maze learning disorder as a model with the condition of the disease. Specifically, it followed the method described in J Pharmacol Exp Ther, 1996; 279: 1157-73, Yamazaki M. et al.


As a result of this test, it was confirmed that compound of formula (I) has effect on dementia.


Test Example 7
Evaluation of Drug in Forced Swimming Test in DBA/2 Mouse

The improvement effect of compound of formula (I) on depression can be evaluated by a known forced swimming test as an evaluation model. Specifically, it follows the method described in “Behav Brain Res. 2005; 156(1): 153-162, Ducottet C. et al.)”.


From the test results of Test Examples 1 to 7, it was confirmed that compound of formula (I) can be used as an agent for treating or preventing 5-HT5A-related diseases, in particular, treating or preventing dementia, schizophrenia (including symptoms such as positive symptoms, negative symptoms, cognitive impairment, mood disorders, and the like), bipolar disorder, attention deficit hyperactivity disorder, psychological disorders (anxiety disorder, panic disorder, obsessive disorder, and the like), autism, mood disorders (anxiety disorder and depression disorder), somnipathy, neurodegenerative diseases, and cerebral infarction.


A pharmaceutical preparation containing one or two or more kinds of compound of formula (I) or a salt thereof as an active ingredient can be prepared by using pharmaceutical carriers, excipients, and the like that are each usually used in the art, by a method that is usually used.


Administration may be made in any form for either oral administration by tablets, pills, capsules, granules, powders, and solutions, or parenteral administration by injections for intraarticular injection, intravenous injection, and intramuscular injection, suppositories, ophthalmic solutions, ophthalmic oinments, percutaneous liquids, oinments, percutaneous patches, transmucosal liquids, transmucosal patches, and inhalations.


Regarding the solid composition for oral administration according to the present invention, tablets, powders, granules, or the like are used. In such a solid composition, one, or two or more active ingredients are mixed with at least one inactive excipient such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, and/or magnesium meta-silicate alminate. According to a conventional method, the composition may contain inactive additives; for example, a lubricant such as magnesium stearate, a disintegrator such as carboxymethylstarch sodium, a stabilizing agent, and a dissolution promotor. As occasion demands, tablets or pills may be coated with a sugar, or a film of a gastric or enteric material.


The liquid composition for oral administration includes pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, and the like, and contains an inert diluent that is commonly used, such as purified water or ethanol. In addition to the inert diluent, this liquid composition may contain an auxiliary agent such as a solubilizing agent, a moistening agent, and a suspending agent, a sweetener, a flavor, an aroma, and an antiseptic.


Injections for parenteral administration include aqueous or non-aqueous sterile solutions, suspensions, and emulsions. Examples of the aqueous solvent include distilled water for injection, and physiological saline. Examples of the non-aqueous solvent include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and Polysorbate 80 (Pharmacopeia). Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a dissolution promotor. These are sterilized, for example, by filtration through a bacterium-retaining filter, blending of bactericides, or irradiation. In addition, these can also be used by producing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile solvent for injection prior to its use.


Examples of the drug for external use include ointments, plasters, creams, jellies, cataplasms, sprays, lotions, ophthalmic solutions, and ophthalmic ointments. The drug contains commonly used ointment bases, lotion bases, aqueous or non-aqueous solutions, suspensions, emulsions, and the like. Examples of the ointment bases or lotion bases include polyethylene glycol, propylene glycol, white vaseline, bleached bee wax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, and sorbitan sesquioleate.


A transmucosal agent such as an inhalations and a transnasal agent can be used in a solid, liquid or semi-solid state, and may be produced in accordance with a conventionally known method. For example, a known excipient, and also a pH adjusting agent, an antiseptic, a surfactant, a lubricant, a stabilizer, a viscosity-increasing agent, and the like may be appropriately added thereto. For their administration, an appropriate device for inhalation or blowing may be used. For example, a compound may be administered alone or as a powder of a formulated mixture, or as a solution or suspension by combining it with a pharmaceutically acceptable carrier, using a conventionally known device or sprayer, such as a measured administration inhalation device. The dry powder inhaler or the like may be for single or multiple administration use, and a dry powder or a powder-containing capsule may be used. Alternatively, this may be in a form such as a high pressure aerosol spray which uses an appropriate propellant, for example, a suitable gas such as chlorofluoroalkane, hydrofluoroalkane, or carbon dioxide.


It is suitable that the daily dose is usually from about 0.0001 to 100 mg/kg per body weight in the case of oral administration, preferably 0.0001 to 10 mg/kg, and even more preferably 0.0001 to 1 mg/kg, and the preparation is administered in one portion or dividing it into 2 to 4 portions. Also, in the case of intravenous administration, the daily dose is administered suitably in a range from about 0.00001 to 1 mg/kg per body weight, and the preparation is administered once a day or two or more times a day. In the case of drugs for external use or transmucosal administration, the drug is administered usually in a range from about 0.0001 to 10 mg/kg per body weight, once a day or two or more times a day. The dose is appropriately decided, depending on individual cases by taking into consideration the symptom, age, sex and the like. The content of the active ingredients in the preparation is from 0.0001 to 50%, and more preferably 0.001 to 50%.


Compound of formula (I) can be used in combination with various therapeutic agents or prophylactic agents for the diseases, in which compound of formula (I) is considered effective, as described above. The combined preparation may be administered simultaneously; or separately, and continuously or at a desired time interval. The preparations to be co-administered may be a blend, or prepared individually.


INDUSTRIAL APPLICABILITY

Compounds of formula (I) have potent 5-HT5A receptor modulating action, and excellent pharmacological action based on said 5-HT5A receptor modulating action. Pharmaceutical compositions of the present invention are useful for treatment or prevention of 5-HT5A receptor-related diseases, and in particular, for treatment or prevention of dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.

Claims
  • 1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
  • 2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z1 is a nitrogen atom, Z2, Z3, Z4 and Z5 are carbon atoms, the ring group A is phenyl, pyridyl, cyclopropyl, cyclohexenyl, cyclopentenyl, or pyrrolidinyl group, R1, R2 and R3 are each H, lower alkyl, halogen, halogeno-lower alkyl, —CN, or —ORa, R4, R5 and R6 are each H, lower alkyl, cyclopropyl, halogen, halogeno-lower alkyl, —CN, or —C(O)NRbRc, and R7 and R8 are both H.
  • 3. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z3 is a nitrogen atom, Z1, Z2, Z4 and Z5 are carbon atoms, the ring group A is phenyl, pyridyl, cyclopropyl, cyclohexenyl, cyclopentenyl, or pyrrolidinyl group, R1, R2 and R3 are each H, lower alkyl, halogen, halogeno-lower alkyl, —CN, or —ORa, R4, R5 and R6 are each H, lower alkyl, cyclopropyl, halogen, halogeno-lower alkyl, —CN, or —C(O)NRbRc, and R7 and R8 are both H.
  • 4. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z1 is a nitrogen atom, Z2, Z3, Z4 and Z5 are carbon atoms, the ring group A is phenyl or pyridyl group, R1, R2 and R3 are each H, F, Cl, or —ORa group, R4, R5 and R6 are each H, lower alkyl, F, Cl, or halogeno-lower alkyl group, and R7 and R8 are both H.
  • 5. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z3 is a nitrogen atom, Z1, Z2, Z4 and Z5 are carbon atoms, the ring group A is phenyl or pyridyl group, R1, R2 and R3 are each H, F, Cl, or —ORa group, R4, R5 and R6 are each H, lower alkyl, F, Cl, or halogeno-lower alkyl group, and R7 and R8 are both H.
  • 6. A compound or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of: N-(diaminomethylene)-2-methyl-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide,1-(2-chloro-6-fluorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,N-(diaminomethylene)-1-(2,6-difluorophenyl)-4-fluoroisoquinoline-7-carboxamide,1-(2-chloro-4-fluorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,N-(diaminomethylene)-4-methyl-1-(2,4,6-trifluorophenyl)isoquinoline-7-carboxamide,N-(diaminomethylene)-2,3-dimethyl-4-(2,4,6-trifluorophenyl)quinoline-6-carboxamide,N-(diaminomethylene)-1-(3,5-difluoropyridin-4-yl)-4-fluoroisoquinoline-7-carboxamide,N-(diaminomethylene-4-fluoro-1-(2-fluoro-6-methoxyphenyl)isoquinoline-7-carboxamide,N-(diaminomethylene)-4-fluoro-1-(2-fluorophenyl)isoquinoline-7-carboxamide,1-(2-chlorophenyl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,4-chloro-N-(diaminomethylene)-1-(2,6-difluorophenyl)isoquinoline-7-carboxamide,1-(3-chloro-5-fluoropyridin-4-yl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,N-(diaminomethylene)-1-(2,6-difluorophenyl)-4-methylisoquinoline-7-carboxamide,1-(3-chloro-5-fluoropyridin-2-yl)-N-(diaminomethylene)-4-fluoroisoquinoline-7-carboxamide,N-(diaminomethylene)-4-(difluoromethyl)-1-(2,6-difluorophenyl)isoquinoline-7-carboxamide,N-(diaminomethylene)-1-(2-fluorophenyl)-4-methylisoquinoline-7-carboxamide, and4-chloro-N-(diaminomethylene)-1-(2,4-difluorophenyl)isoquinoline-7-carboxamide.
  • 7. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.
  • 8. The pharmaceutical composition according to claim 7 which is a 5-HT5A receptor inhibitor.
  • 9. The pharmaceutical composition according to claim 8 which is an agent for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.
  • 10. Use of the compound or a pharmaceutically acceptable salt thereof according to claim 1 for prevention or treatment of dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.
  • 11. Use of the compound or a pharmaceutically acceptable salt thereof according to claim 1 for the manufacture of an agent for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.
  • 12. A method for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, comprising administering a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient.
Priority Claims (1)
Number Date Country Kind
2009-183876 Aug 2009 JP national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/JP2010/063240 8/5/2010 WO 00 2/3/2012